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ABSTRACT OF DISSERTATION 
 
 
 
MUTATIONS OF FUS CAUSE AGGREGATION OF RNA BINDING PROTEINS, 
DISRUPTIONS IN PROTEIN SYNTHESIS, AND DYSREGULATION OF 
NONSENSE MEDIATED DECAY 
 
 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterized by motor neuron death and subsequent muscle atrophy. Approximately 15% 
of ALS cases are inheritable, and mutations in the Fused in Sarcoma (FUS) gene contribute 
to approximately 5% of these cases, as well as about 2% of sporadic cases. FUS performs 
a diverse set of cellular functions, including being a major regulator of RNA metabolism. 
FUS undergoes liquid- liquid phase transition in vitro, allowing for its participation in 
stress granules and RNA transport granules. Phase transition also contributes to the 
formation of cytoplasmic inclusions found in the cell bodies of FUS ALS patients motor 
neurons. The nature of these inclusions has remained elusive, as the proteins localized to 
them have not been identified. Additionally, the functional consequence of the 
accumulation of cytoplasmic FUS inclusions has not been established, nor is it understood 
how they contribute to selective motor neuron death. 
 We carried out two related, but independent studies to characterize the proteins that 
may be included in FUS-positive inclusions. In this first study, we utilized 
immunoprecipitation of wild-type and mutant FUS in the presence and absence of RNase, 
followed by LC MS/MS. The identified proteins represent those that directly or indirectly 
interact with FUS, with relatively high affinity that can be pulled down with 
immunoprecipitation. A wide variety of interacting proteins were identified and they are 
involved in a multitude of pathways including: chromosomal organization, transcription, 
RNA splicing, RNA transport, localized translation, and stress response. Their interaction 
with FUS varied greatly in their requirements for RNA. Most notably, FUS interacted with 
hnRNPA1 and Matrin-3, proteins also known to cause familial ALS. Immunofluorescent 
     
 
staining of proteins interacting with mutant FUS were localized to cytoplasmic inclusions. 
We concluded that mis-localization of these proteins potentially lead to their dysregulation 
or loss of function, thus contributing to FUS pathogenesis. 
 In the second study, we developed a protocol to isolate dynamic FUS inclusions 
and employed LC MS/MS to identify all proteins associated with FUS inclusions. We 
identified a cohort of proteins involved in translation, splicing, and RNA export to be 
associated with the FUS inclusions. Further pathway and disease association analysis 
suggested that proteins associated with translation and RNA quality control pathways may 
be the most significant. Protein translation assays using both N2A and ALS patient 
fibroblasts demonstrated suppression of protein biosynthesis in mutant FUS expressing 
cells. However, translation initiation was not impaired. To understand how protein 
synthesis is suppressed by mutant FUS mediated defects in RNA metabolism, we examined 
changes in a well conserved RNA turnover pathway namely: nonsense mediated decay 
(NMD). We found that NMD is hyperactivated in cells expressing mutant FUS, likely due 
to chronic suppression of protein translation shifting the pathways autoregulatory circuit to 
allow for hyperactivation.  We concluded that mutant FUS suppresses protein biosynthesis 
and disrupts NMD regulation. These defects together likely contribute to motor neuron 
death. 
 
KEYWORDS: Fused in Sarcoma, Amyotrophic Lateral Sclerosis, RNA binding, Nonsense 
Mediated Decay, Protein Translation. 
  
 
 
 
 
 
 
 
 
 
 
 
Marisa Elizabeth Kamelgarn 
(Name of Student) 
 
[03/22/2019] 
            Date 
 
  
iii 
 
 
 
 
 
 
 
 
 
MUTATIONS OF FUS CAUSE AGGREGATION OF RNA BINDING PROTEINS, 
DISRUPTIONS IN PROTEIN SYNTHESIS, AND DYSREGULATION OF 
NONSENSE MEDIATED DECAY 
 
By 
Marisa Elizabeth Kamelgarn 
 
 
 
 
 
 
 
 
 
 
 
Dr. Haining Zhu 
Director of Dissertation 
 
Dr. Isabel Mellon 
Director of Graduate Studies 
 
03/22/2019 
            Date
 
 
 
iii 
ACKNOWLEDGMENTS 
This dissertation and the research done would not have been possible without the 
guidance and support of Dr. Haining Zhu, the Zhu lab, and my family and friends. I would 
like to thank my advisor Dr. Zhu for the opportunity to work in his lab and his help 
developing this project. The freedom he afforded me in the lab helped develop my skills 
as an independent scientist, an invaluable part of my training that will be essential for   my 
career. Not only has Dr. Zhu been an incredible mentor, helping foster creativity at the 
bench, but also encouraging perseverance and instilling confidence in my research. I 
would also like to thank my Advisory Committee: Drs. Isabel Mellon, Daret St. Clair, 
Edward J. Kasarskis, and Stefan Stamm for the time spent on collaborations, committee 
meetings, exams, and reference letters, and for the great  advice  and  suggestions on my 
research projects. Lastly, I would like to give a special thanks to Dr. Steven Estus for 
serving as Outside Examiner of my final exam. 
In nearly six years, I have made some incredible friends in the Zhu Lab. I want to 
give special thanks to Ms. Li Liu for taking care of basic lab needs and for helping breed 
mice for primary neuron culture. I also want to thank current and previous members of the 
Zhu Lab: Drs. Liuqing Yang, Junkai Fan, Dandan Liu, Jozsef Gal, Jing Chen, Lisha 
Kuang, and Sushil Dubey, as well as Alexandra Arenas and Will Na. I would like to extend 
a special thank you to Huan Jin, for producing data published in our PNAS paper. 
I want to thank the department of Toxicology and Cancer Biology for providing 
both financial and educational support, as well as the department of Molecular and 
Cellular Biochemistry for allowing me to use their facilities. Both departments have 
 
 
 
iv 
amazing professors, staff, postdocs, and students. I would like to give a very special thank 
you to Dr. Isabel Mellon for her guidance, support, and the opportunity to host the 
Toxicology Student Forum. Additionally, I would like to thank Ms. Madalyn Willis for 
helping take care of my student affairs and Dr. Carole Moncman for training me on the 
confocal microscope. I am forever grateful for everyone’s assistance and guidance, and 
proud that I can take the skills you all have taught me to future research positions. 
Lastly, I would like to thank my parents, Sandra and Howard Kamelgarn for their 
support over the past five and half years, as well as my fiancée Eugene Hinderer III for his 
support. 
This dissertation research would not have been possible without the funding 
support from: the department of Toxicology and Cancer Biology’s T32 training grant, the 
College of Medicine’s Fellowship for Excellence in Graduate Research Award, the Lyman 
T. Johnson Fellowship, National Institute of Neurological Disorder, Stroke (NINDS) and 
Amyotrophic Lateral Sclerosis (ALS) Association, and the Veterans Association (VA). 
 
 
 
 
 
 
 
 
 
 
v 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................ iii 
TABLE OF CONTENTS................................................................................................... v 
LIST OF TABLES .........................................................................................................viii 
LIST OF FIGURES ......................................................................................................... ix 
LIST OF ADDITIONAL FILES ........................................................................................ x 
CHAPTER 1. Introduction ..............................................................................................1 
1.1 What is Amyotrophic Lateral Sclerosis? ...........................................................1 
1.2 FUS’ Domain Structure and Post Translational Modifications ..........................2 
1.3 FUS’ Nuclear Function ....................................................................................3 
 Transcription ................................................................................................4 
 Regulation of mRNA Length and Coupling Transcription to Splicing...........6 
 Alternative Splicing ......................................................................................7 
1.4 Nucleocytoplasmic Shuttling of FUS .............................................................. 10 
1.5 FUS’ Cytoplasmic Function ........................................................................... 12 
 Protein Translation ..................................................................................... 12 
 RNA Triage and Stress Response ............................................................... 13 
 Regulation of RNA Stability ....................................................................... 14 
1.6 Study Rationale and Overview ....................................................................... 16 
CHAPTER 2. Materials and Methods ........................................................................... 23 
2.1 Cell Culture, Plasmids, and Transfection ........................................................ 23 
2.2 Culture and Transfection of Primary Cortical Neurons ................................... 23 
2.3 GST-FUS Pull-Downs .................................................................................... 24 
2.4 Immunoprecipitation ...................................................................................... 24 
2.5 Proteomic identification of FUS interaction partners ...................................... 25 
2.6 Western Blot .................................................................................................. 26 
2.7 Immunofluorescence microscopy ................................................................... 27 
2.8 Patient Skin Fibroblast Culture ....................................................................... 27 
2.9 Membrane Filtration ....................................................................................... 28 
2.10 Native Gel Electrophoresis ............................................................................. 28 
2.11 Proteomic identification of proteins captured by membrane filtration ............. 29 
 
 
 
vi 
2.12 Enrichment Analysis of roteins captured by membrane filtration .................... 29 
2.13 RNA FISH ..................................................................................................... 30 
2.14 RNA Immunoprecipitation followed by qPCR ............................................... 30 
2.15 Protein Translation Assays ............................................................................. 31 
2.16 7’ Methyl-guanosine Pulldown ....................................................................... 32 
2.17 Bromouridine Immunoprecipitation................................................................ 32 
2.18 NMD Activity Assays .................................................................................... 33 
2.19 RNA Stability Assay ...................................................................................... 33 
2.20 Statistics ......................................................................................................... 34 
CHAPTER 3. Proteomic Analysis of FUS Interacting Proteins Provides Insights Into 
FUS Function and Its Role in ALS ................................................................................. 38 
3.1 Introduction.................................................................................................... 38 
3.2 Results ........................................................................................................... 40 
 Identification of FUS interaction partners ................................................... 40 
 Validation and characterization of selected FUS interactions ...................... 41 
 Co-localization of FUS interaction partners with cytoplasmic ALS mutant 
FUS inclusions ....................................................................................................... 42 
 Significantly enriched Gene Ontology (GO) terms among the identified FUS 
interacting partners ................................................................................................ 44 
 FUS interacts with overlapping ribonucleoprotein complexes ..................... 45 
3.3 Discussion ...................................................................................................... 47 
 Identification and validation of FUS interaction partners ............................ 47 
 The RNA dependence of FUS interactions ................................................. 48 
 The interaction of FUS with the ALS-related proteins Matrin-3 and 
hnRNPA1 .............................................................................................................. 49 
 FUS interacts with regulators of protein phosphorylation............................ 49 
 Loss of nuclear FUS functions due to ALS mutations ................................. 50 
 Mis-regulation of cytoplasmic processes by ALS mutant FUS .................... 51 
3.4 Conclusions.................................................................................................... 52 
CHAPTER 4. ALS Mutations of FUS Suppress Protein Translation and Disrupt the 
Regulation of Nonsense-Mediated Decay ....................................................................... 66 
4.1 Introduction.................................................................................................... 66 
4.2 Results ........................................................................................................... 68 
 Proteins related to translation and mRNA surveillance are enriched in mutant 
FUS inclusions. ...................................................................................................... 68 
 Protein translation is impaired in the presence of mutant FUS .................... 70 
 The NMD pathway is activated by mutant FUS .......................................... 73 
 NMD factors are dysregulated in fibroblasts in FUS ALS cases .................. 75 
 
 
 
vii 
 UPF1-mediated autoregulation of NMD is impaired in FUS ALS cases ...... 76 
 Enhanced decay of NMD substrate in the presence of ALS mutant FUS ..... 77 
4.3 Discussion ...................................................................................................... 79 
CHAPTER 5. The Role of Endogenous FUS in Nonsense Mediated Decay ................. 110 
5.1 Introduction.................................................................................................. 110 
5.2 Results ......................................................................................................... 112 
 FUS Binds NMD Factor mRNA ............................................................... 112 
 FUS Binds NMD Substrate mRNA .......................................................... 113 
 FUS Knockout Downregulates Pro-NMD Factor Proteins ........................ 114 
 FUS KO Reduces NMD Complex Assembly ............................................ 115 
 FUS Knockout Downregulates Pro-NMD Factor mRNA .......................... 115 
 Stability of NMD Factors is Unchanged when FUS is Knocked Out ......... 116 
 FUS KO Reduces UPF1 Binding to NMD Factor mRNA ......................... 116 
 NMD Substrate mRNAs are Stabilized when FUS is Knocked Out .......... 117 
 FUS KO Reduces UPF1 Binding to NMD Substrate mRNA ..................... 118 
 Natural NMD substrate levels are in influenced by FUS KO ................. 118 
5.3 Conclusions and Future Directions for FUS KO/ NMD Study ...................... 119 
REFERENCES ............................................................................................................ 136 
Vita.............................................................................................................................. 154 
 
 
 
  
 
 
 
 
viii 
LIST OF TABLES 
Table 2.1 Patient Fibroblasts .......................................................................................... 35 
Table 2.2 List of qPCR Primers ..................................................................................... 36 
Table 3.1 Selected enriched GO Biological Processes among the identified FUS 
interacting partners. ............................................................................................... 53 
Table 3.2 Selected enriched GO Molecular Functions among the identified FUS 
interacting partners. ............................................................................................... 54 
Table 3.3 Selected enriched GO Cellular Components among the identified FUS 
interacting partners. ............................................................................................... 55 
 
 
 
ix 
LIST OF FIGURES 
Figure 1.1 FUS Domain Structure .................................................................................. 18 
Figure 1.2 FUS Nuclear Functions ................................................................................. 19 
Figure 1.3 FUS' Cytoplasmic Function .......................................................................... 21 
Figure  3.1 ..................................................................................................................... 56 
Figure 3.2 ...................................................................................................................... 57 
Figure 3.3 ...................................................................................................................... 58 
Figure 3.4 ...................................................................................................................... 60 
Figure 3.5 ...................................................................................................................... 62 
Figure 3.6 ...................................................................................................................... 64 
Figure 3.7 ...................................................................................................................... 65 
Figure 4.1 ...................................................................................................................... 85 
Figure 4.2 ...................................................................................................................... 87 
Figure 4.3 ...................................................................................................................... 88 
Figure 4.4 ...................................................................................................................... 89 
Figure 4.5 ...................................................................................................................... 90 
Figure 4.6 ...................................................................................................................... 92 
Figure 4.7 ...................................................................................................................... 93 
Figure 4.8 ...................................................................................................................... 95 
Figure 4.9 ...................................................................................................................... 97 
Figure 4.10 .................................................................................................................... 98 
Figure 4.11 .................................................................................................................... 99 
Figure 4.12 .................................................................................................................. 101 
Figure 4.13 .................................................................................................................. 102 
Figure 4.14 .................................................................................................................. 104 
Figure 4.15 .................................................................................................................. 106 
Figure 4.16 .................................................................................................................. 107 
Figure 4.17 .................................................................................................................. 109 
Figure 5.1 Endogenous FUS binds key NMD factor mRNA ........................................ 122 
Figure 5.2 Endogenous FUS binds NMD substrate mRNA .......................................... 123 
Figure 5.3 Endogenous FUS is required for normal expression of NMD factor protein 124 
Figure 5.4 Endogenous FUS is required for assembly of NMD factor complexes ......... 126 
Figure 5.5 Endogenous FUS is required for normal expression of NMD factor mRNA 127 
Figure 5.6 NMD factor mRNA stability is unchanged when FUS is Knocked Out ....... 128 
Figure 5.7 FUS KO Reduces UPF1 Binding to NMD Factor mRNA............................ 129 
Figure 5.8 NMD substrate mRNA is stabilized when FUS is Knocked Out .................. 131 
Figure 5.9 UPF1 Binding to NMD Substrate mRNA is Reduced When FUS is Knocked 
Out ...................................................................................................................... 132 
Figure 5.10 Natural NMD substrate levels are in influenced by FUS KO ..................... 134 
 
 
 
x 
 
LIST OF ADDITIONAL FILES 
 
Supplemental Table 3.1. The identified non-ribosomal FUS interacting 
partners………………………………………………………………………[PDF 176 KB] 
Supplemental Table 3.2. The identified ribosomal FUS interacting partners.…..[PDF 133 KB] 
Supplemental Table 4.1 FUS WT Proteomics ………………….………….. [PDF 1.2 MB] 
Supplemental Table 4.2. FUS R495X Proteomics …..……..............…….... [PDF 1.1 MB] 
Supplemental Table 4.3 FUS P525L Proteomics …..………...…….…....… [PDF 1.1 MB] 
Supplemental Table A. List of Primers ……….. ……..…….......…….......... [PDF 154 KB] 
 
 
 
1 
CHAPTER 1. INTRODUCTION 
1.1 What is Amyotrophic Lateral Sclerosis? 
 Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressing, neurodegenerative 
disease impacting both upper and lower motor neurons. Brought into the public eye in the 
1930s by the American baseball player, Lou Gehrig, the disease is characterized by body-
wide voluntary muscle weakness and paralysis, culminating in the death of the patient (1). 
According to the ALS Association, in the United States alone, there are approximately 
20,000 individuals living with ALS and 6,000 new diagnoses each year. ALS can be 
classified as sporadic (sALS), where no family history of the disease is found, or familial 
(fALS) if a mutated allele is identified in several family members with the disease. Roughly 
90% of ALS cases are considered sporadic, while the remaining 10% are from inheritable 
mutations. Genes most commonly mutated that result in an ALS phenotype are C9orf72, 
Superoxide Dismutase I (SOD1), transactive response DNA binding protein 43 kDa (TPD-
43), and Fused in Sarcoma (FUS) (1).  
 FUS is a DNA and RNA binding protein identified in 2009 to cause approximately 
5% of fALS and 2% of sALS cases when mutated (2, 3). Although FUS mutations are 
considered rare and only account for 5% of fALS cases, it accounts for approximately 60% 
of all fALS cases for patients younger than 40 years of age (4, 5). The severity of FUS 
related ALS varies, with specific mutations resulting in a shorter course of disease earlier 
in life. Severe, disease-causing mutations typically result in FUS’ mis-localization from 
the nucleus to the cytoplasm. Presentation of FUS in the cytoplasm can vary in appearance, 
depending on the type of mutation an individual has (5). Mutant FUS’ presentation in the 
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cytoplasm may range from diffuse throughout the cytoplasm to forming large inclusion 
bodies. These inclusions are basophilic, and ubiquitin and p62 positive (6, 7), however, the 
consequence of their formation in the cell body of motor neurons is unknown. Wild type 
FUS’ cellular functions have been well characterized and include transcription, regulation 
of RNA length, alternative splicing, nucleocytoplasmic export, protein translation, and 
maintenance of RNA stability.  
1.2  FUS’ Domain Structure and Post Translational Modifications 
 FUS is a member of the FUS, EWSR1, TAF15 (FET) family of DNA and RNA 
binding proteins. These proteins are composed of a unique set of a prion-like QGYS 
domains, two RNA-recognition motifs (RRM), a zinc-finger (ZnF) domain, and a C-
terminal nuclear localization domain (5). To better understand FUS’ molecular function, 
several in-depth studies have been conducted to understand the importance of each domain. 
FUS’ QGYS, or low-complexity (LC), domain has been characterized using NMR. It was 
determined to have a unique amino acid profile and folding dynamics compared to many 
other intrinsically disordered, neurodegenerative proteins (8). FUS’ QGYS domain is 
required for formation of functional oligomeric species that can be regulated through 
phosphorylation of serine and threonine residues. Phosphorylation of these sites facilitates 
disassembly of liquid/liquid droplets formed by FUS and prevent its aggregation (8, 9). 
RNP granules formed through the QGYS domain are critical for regulation of mRNA 
stability, location, and metabolism, most notably the formation of stress granules (SGs) in 
times of acute cellular stress (10-12).  
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 In addition to self-oligomerization being required for RNP granule formation and 
binding RNA polymerase 2 (RNAP2), RNA binding is also needed for seeding these 
complexes (13, 14). FUS’ nucleotide (DNA and RNA) binding function is executed 
through its RGG, RRM and ZnF domains (15, 16). Little is understood about the 
mechanism through which the domains determine nucleotide binding specificity, however, 
this aspect of FUS’ structure is central to its natural cellular function, as well as its disease 
phenotype. FUS’ RGG and RRM domains can be methylated on arginine residues. 
Arginine methylation is important for regulating FUS’ participation in phase separation 
and transportin-1 (TNPO1) binding. It has been reported that disruption of FUS’ 
methylation profile, characteristic of FUS mutations contributes to cytoplasmic mis-
localization and stabilization of oligomeric structures (17, 18). Together, FUS’ amino acid 
sequence, domains, and types of post-translational modifications are critical for its 
localization and function in motor neurons (Fig. 1.1). Disturbance in one of these features 
due to an ALS causing mutation leads to gross changes in FUS’ molecular function and 
contributes to a neurodegenerative phenotype.  
1.3 FUS’ Nuclear Function 
 FUS is largely a nuclear protein that plays critical roles in transcription, mRNA 
maturation, and nucleocytoplasmic export of RNA (Fig. 1.2). It is hypothesized that the 
first step in cellular dysfunction contributing to ALS pathogenesis is FUS’ exclusion from 
the nucleus (19). Exclusion of FUS from the nucleus may result in defective transcription, 
polyadenylation, and splicing of mRNA. FUS’ structure is critical to its normal function in 
the nucleus and is vital to maintaining the fidelity of the transcriptome.  
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 Transcription 
 FUS is a potent regulator of RNA synthesis that can bind active chromatin. There 
are two nuclear pools of FUS: a soluble fraction and chromatin bound fraction (20). It is 
likely that the chromatin bound fraction contains FUS interacting with RNAP2 and directly 
with DNA. The soluble fraction is FUS bound to newly synthesized RNA, regulating 
splicing and processing mRNA for nuclear export (20). These observations are supported 
by FUS knockout experiments that describe lost expression of hundreds of genes (21). 
Additionally, formation of oligomeric species is required for WT and mutant FUS to 
interact with active chromatin in discreet nuclear puncta (20, 22), indicative of localization 
to sites of active transcription (23). Mutations that lead to exclusion of FUS from the 
nucleus have fewer active sites and repression of transcription (20, 22).  
 FUS’ interaction with RNAP2 is critical for its role in the regulation of gene 
expression. Accumulation of FUS at transcriptional start sites (TSS) recruits RNAP2 to 
active chromatin (20, 22). Following recruitment, FUS binds the C-terminal domain (CTD) 
of RNAP2, where it regulates its phosphorylation state of specific serine residues. 
Classically, there are two positions within the CTD that promote or block RNAP2 
translocation along DNA: serine 2 (Ser2) and serine 5 (Ser5). Upon FUS knockdown, 
studies demonstrated the accumulation of phosphorylation on Ser2 (13) (p-Ser2), which is 
illustrative of transcriptional termination (24, 25). These knockdown studies demonstrated 
that FUS limits p-TEFb phosphorylation of Ser2, implying that FUS functions to prevent 
premature termination of transcription (13). However, as RNAP2 travels down the DNA, 
p-Ser2 collects on the CTD, which eventually displaces FUS and terminates transcription 
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(26). Studies in ALS patient fibroblasts exhibited similar changes in the phosphorylation 
state of Ser2 as observed in FUS knockdown cells, indicating that mutations in FUS result 
in a nuclear loss of function (23). Mutant FUS has been observed to localize within nuclear 
aggregates sequestered away from TSS’ and RNAP2. This sequestration away from 
transcriptionally active chromatin and RNAP2 likely leads to premature phosphorylation 
of Ser2 near the TSS and reduced mRNA levels (23).  
 Deeper explorations of differences between how mutant and WT FUS bind 
transcriptionally active chromatin demonstrate the importance of oligomerization and 
RNA binding. Both forms of the protein bind chromatin through their LC-domains and 
RNA through FUS’ RGG-Zn-RGG domains (13, 27). However, compared to WT FUS, 
mutant FUS has reduced chromatin binding capabilities, and therefore some loss of nuclear 
function (20). In fact, FUS’ LC-domain is required for interaction with chromatin, binding 
RNAP2, and effective transcription, suggesting that formation of functional oligomers is 
intrinsic for FUS’ nuclear function (20).  
 Taken together, FUS is an important regulator of transcription through several 
different modalities. Endogenous FUS influences transcriptional activity through directly 
binding to chromatin and to RNAP2. These interactions are critical to signal for 
transcription to be initiated for a specific gene, but also to enhance complete RNA 
synthesis.  
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 Regulation of mRNA Length and Coupling Transcription to Splicing 
 FUS plays an important role in post-transcriptionally modifying mRNA to control 
gene expression in tandem with transcription. Connection of transcription to mRNA 
splicing and polyadenylation is an important step in efficient maturation of mRNA. 
Without these processes, transcription would terminate prematurely, and newly 
synthesized mRNA would undergo premature polyadenylation (28, 29).  
 FUS is a potent regulator of mRNA length through selection of favorable 
polyadenylation sites for expression of approximately two-thirds of neuronal genes (30). 
FUS’ binding to nascent RNA, in combination to direct interaction with RNAP2, 
determines transcriptional termination and polyadenylation (30). To regulate 
polyadenylation, FUS binds upstream (5’) or downstream (3’) of alternative 
polyadenylation (APA) sites (30). The location of FUS’ binding site on RNA determines 
whether the short polyA or degraded isoform is favored. For short APA isoforms, FUS 
binds downstream (3’) from the APA site, which enhances the RNA’s interaction with 
RNAP2, allowing polyadenylation specificity factor (CPSF) complex members to bind, 
specifically, CPSF160. This interaction generates short polyA tails and stimulates 
additional proteins to bind and finish synthesizing sequence (31, 32). Conversely, if FUS 
binds upstream (5’) of an APA site, RNAP2 stalls and terminates transcription, leading to 
truncated transcripts that are degraded (30).  
 Studies exploring the consequences of FUS’ loss of function in motor neurons 
demonstrated dysregulation of transcription and polyadenylation (30, 33). For example, 
FUS knockdown caused APA sites to be differentially regulated for genes relating to 
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synaptic activity and motor neuron-specific activity (30). More research needs to be done 
looking into changes in transcription and polyadenylation that occur when FUS is mutated 
to gain a deeper understanding of how ALS mutations of FUS directly the transcriptome.  
 Alternative Splicing  
FUS’ interaction with RNA is complicated; several different groups have identified various 
sequences and secondary characteristics that FUS preferentially interacts with, however, 
an agreement as to FUS’ specificity has not been reached in the field. Preliminary studies 
identified a GGUG consensus sequence that facilitated FUS binding through its RRM 
domain (34, 35). Advancements in technology have allowed us to identify specific 
secondary structures and G/C or A/U rich regions FUS also binds (21, 36, 37). Although 
no definitive sequence FUS binds to has been identified, the protein broadly clusters around 
the 5’ ends of long introns (21, 30, 37, 38), as well as within introns of cassette exons (30, 
39).  
 This consistent binding pattern of FUS to binding 5’ ends of introns and within 
cassette exons illustrates FUS’ important role as a regulator of alternative splicing. 
Explorations of functional defects caused by FUS knockout in neurons demonstrated 
changes in splicing of over 3,000 exons and expression changes in 183 genes (30). Of the 
183 genes exhibiting the most significant alterations in their splicing profiles, several were 
involved in neuronal function and neurodegeneration. They include Mapt, Camk2a, and 
Fmr1 (30). Additionally, annotation enrichment of genes regulated by FUS, demonstrated 
its importance in neuronal gene expression. Terms such as “neuronal impulse”, “neuronal 
projection”, and “vesicle transport” were enriched (30). Studies investigating FUS’ binding 
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pattern within introns demonstrated enrichment within genes of RNA binding proteins in 
mouse and human brains, as well. The intronic sequences FUS binds are highly conserved 
and upon FUS knockout, are retained within the mature mRNA (35). Overall, FUS’ binding 
of introns is required for normal expression of genes required for neuronal function and 
RNA metabolism. However, FUS’ ability to regulate splicing is done in conjunction with 
other splicing factors. 
 FUS’ role in regulation of splicing largely involves its interaction with U1snRNP 
and other splicing factors (40-43). Perhaps one of FUS’ best-understood protein/protein 
relationships is between U1snRNP and Survival Motor (SMN), the protein responsible for 
Spinal Muscular Atrophy (SMA). U1snRNP is a core spliceosomal component responsible 
for recognizing the 5’ splice site of an intron, the first step in the classical splicing pathway 
(44). During transcription, FUS recruits U1snRNP to 5’ ends of introns to begin assembly 
of splicing complex members (45). Studies utilizing ALS FUS mutants observed reduction 
of U1snRNP/pre-mRNA interaction. This is likely due to defective interactions between 
mutant FUS and U1snRNP, U1snRNP’s mis-localization to the mutant FUS inclusion, and 
an overall reduction of U1snRNA bioavailability due to defective SMN activity (40, 41).  
 SMN is considered to be the master of snRNP biogenesis (46) and mRNP assembly 
on pre-mRNA (47, 48), however, this is not without the help of FUS. WT and mutant FUS 
have been shown to directly bind to SMN and SMN complex members (42). Mutations in 
FUS disturb SMN’s localization due to sequestration of SMN in cytoplasmic FUS 
inclusions, thus reducing its nuclear availability and the number of Gems (40, 42). Gems 
are SMN-dependent sites of snRNA biosynthesis (49). Mutations in FUS mimic the same 
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loss of Gems observed in FUS KO cells, resulting in the reduction in snRNA synthesis. 
These patterns are observed in patient fibroblasts, transfected cells, and in transgenic 
mouse models of FUS ALS (40, 42). This is likely due to reductions in the levels of select 
snRNAs. In addition to disrupting snRNP biogenesis, in a mouse motor neuron model of 
mutant FUS, localization of SMN to cytoplasmic inclusions leads to reduced axonal SMN, 
contributing to axonal defects (50).  
 Together, interaction between mutant FUS, U1snRNP, and SMN illustrate the 
detrimental effects that occur when FUS is mutated. FUS mutations lead to a complex 
cytoplasmic toxic gain of function/nuclear loss of function phenotype across disease 
models. FUS’ toxic sequestration of U1snRNP and SMN in cytoplasmic inclusions 
contributes to splicing defects illustrative of nuclear loss of function. Overall, the splicing 
defects that arise for loss of snRNPs and FUS are vast, negatively impact normal neuronal 
function, and are likely to be a main contributor to motor neuron degeneration.  
 FUS’ role in splicing is not limited to the classical U1 splicing pathway (5, 21, 33, 
35, 37-39, 51, 52). FUS also plays a role in splicing U12-type introns of the minor splicing 
pathway (53). These unique introns comprise approximately 1% of the transcriptome.  Of 
the small subset of transcripts that are included in this group, a member of the voltage-
gated sodium channel required for normal muscle function is included (54, 55). In a 
mechanism similar to U1snRNP dependent splicing, FUS binds the 5’ splice site of introns 
to recruit U11 (53). Moreover, mutations in FUS fail to recruit U11 and U12 to the pre-
mRNA and traps them in cytoplasmic inclusions (53).  
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 Finally, FUS also plays a role in regulation of the circular RNA (circRNA) 
transcriptome. circRNAs are a rare species of RNA that originate from back-splicing events 
in which a downstream 5’ splice site covalently binds with the upstream 3’ splice site (56). 
Their functions in the cytoplasm of cells are still elusive, however, they are thought to act 
as “sponges” for RBPs to regulate their activity (57). In IPSC derived motor neurons 
deficient for FUS, 134 different circular transcripts were discovered to be differentially 
regulated, with 111 being downregulated. In N2a cells expressing FUS P525L and R521C 
ALS mutations, the same pattern of circRNA downregulation was recapitulated, likely due 
to nuclear deficiencies in splicing factors. Further inquiry into FUS’ role in the 
circularization mechanism demonstrated that FUS must bind introns flanking the 
circularized exons (58). This is consistent with data demonstrating that FUS is required to 
bind along introns for alternative splicing to occur (20, 21, 39, 51, 56).  
 Overall, many studies have illustrated FUS’ critical importance in regulating gene 
expression. This regulation and control span from snRNA biogenesis through interaction 
with SMN, to generation of rare circRNA isoforms. FUS’ function in binding the 5’ end of 
introns to recruit splicing factors from the classical and minor splicing pathways 
demonstrate its broad impacts on neuronal gene expression. Changes in gene expression 
and splicing may provide the initial steps in a complex pathogenic mechanism culminating 
in motor neuron death. 
1.4 Nucleocytoplasmic Shuttling of FUS 
 A pathological hallmark of FUS-ALS is accumulation of FUS in cytoplasmic 
inclusion bodies in the somas of motor neurons (2, 3). A long-standing question the field 
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aimed to answer was how and why FUS mutants remain localized to the cytoplasm and 
formed potentially pathological inclusions. An interesting feature of FUS is its non-
canonical nuclear localization sequence (NLS) that binds TNPO1 (59, 60) through 
methylation in its RGG3 domain (18, 61). TNPO1 transports FUS back into the nucleus 
through the nuclear pore complex upon its release from mRNA in the cytoplasm. Mutations 
in FUS, however, impair its TNPO1 interaction due to defective methylation (12, 18, 62, 
63). FUS’ regulation through methylation is a complicated set of events dictated by 
PRMT1 asymmetrically dimethylating FUS. Monomethylated FUS has a much higher 
affinity for TNPO1 and may be responsible for cytoplasmic sequestration of TNPO1 
characteristic of FTLD-FUS (18, 64). In contrast, mutant FUS is hypomethylated in ALS, 
which results in cytoplasmic aggregation (17, 19, 62). It is speculated that neuron sub-type 
specific changes in methylation enzymes account for differences between FTLD and ALS 
(17).  
 Further research into the mechanism that regulates FUS’ re-entry to the nucleus 
illustrates that binding of TNPO1 to FUS’ NLS prevents phase separation required to form 
cytoplasmic aggregates (18). FUS mutants are prone to aggregation due to their reduced 
ability to interact with TNPO1 (18, 65). FUS’ low complexity N-terminal domain naturally 
forms β-sheets through arginine and tyrosine residues interacting via cation-π interactions 
(17). Hypomethylation of these residues promotes phase separation, as it prevents TNPO1 
from acting as a molecular chaperone for FUS in the axons of motor neurons, as well as 
the nuclear pore (17).  
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1.5 FUS’ Cytoplasmic Function 
 FUS’ cytoplasmic role in neurons has yet to be described in detail. Recent 
publications have begun to describe FUS’ role in regulation of stress granule dynamics, 
translation, and regulation of mRNA stability (Fig. 1.3). 
 Protein Translation 
 FUS’ function in regulation of mRNA metabolism is ever evolving. FUS has been 
demonstrated to be shuttled out into the cytoplasm bound to mRNA, then chaperoned back 
into the nucleus. Early in FUS’ characterization, it was linked to translation in adenomatous 
polyposis coli (APC)-RNPs. These granules included RNAs that mediate cell migration. 
Interestingly, both wild type and mutant FUS were localized to these translationally active 
granules in cell protrusions (66), however, the levels of protein biosynthesis were not 
measured. 
 More recently, FUS’ cytoplasmic function has begun to be described in more detail. 
Transgenic mice expressing wild type or the R521 mutant were observed to have defects 
in axonal translation and changes in RNA expression. Specifically, it was reported that 
elevated levels of RNA’s encoding for stress-related chaperones were observed, while 
genes for synaptic function like ion transporters were downregulated (67). This landmark 
paper provides support and a mechanism to a 2015 paper demonstrating the GluA1 subunit 
of the AMPA receptor is downregulated (68). Both groups described behavioral deficits in 
mutant animals, while only the Da Cruz lab identified motor defects. This fascinating 
difference in phenotype is likely due to different neuronal subtypes bearing mutations (67, 
68).   
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 RNA Triage and Stress Response 
FUS involvement in stress granule (SG) formation has been described as a vital function 
of the protein since it was initially implicated in causing ALS. SGs are membrane-less, 
cytoplasmic granules that are sites of arrested translation and temporary mRNA 
stabilization. They function to protect mRNP complexes in times of acute cellular stress. 
Many proteins are recruited into SGs, including wild type and mutant FUS (12, 69). Studies 
that aimed to understand FUS’ role in SG formation utilized FUS KO cells. Ultimately, it 
was found that loss of FUS does not negatively impact SG formation, indicating that FUS 
participates in later stages of stress response and RNA triage (69).  
 To investigate the mechanism by which wild type and mutant FUS localize to the 
cytoplasm, Pandey et.al mutated four phenylalanine residues (F305, F341, F359, and F368) 
to leucine in FUS’ RRM (11). Mutation of these residues abolished FUS’ RNA binding 
ability and resulted in nuclear sequestration of FUS, suggesting that RNA binding is 
required for FUS’ nuclear export and incorporation into SGs (11). Mutant FUS follows 
similar rules for SG incorporation, requiring RNA binding to enter SGs, however, it is 
hypothesized that this initiates the formation of cytoplasmic inclusions. Additionally, FUS 
cannot act alone in managing SGs dynamics. Proteins like G3BP1 and TIA1 also manage 
the longevity, size, and mRNA stability with SGs (70, 71). Changes in the SG proteome 
can account for differences when comparing their formation in WT and mutant FUS cells. 
However, the mechanism driving the potential stabilization of SG’s in cells bearing mutant 
FUS is unknown. 
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 A large variety of proteins can be found localized to the SG- like mutant FUS 
inclusions, however, many are related to RNA binding, SG formation, protein translation, 
and other aspects of RNA metabolism. Early proteometric analysis of FUS’ binding 
partners identified a number of key stress granule proteins, including Poly-A binding 
protein (PABP1). Additionally, FUS inclusions also colocalize with SG markers TIA1, 
Caprin-1, and G3BP1 (70, 72-74). P-bodies are observed adjacent to FUS inclusions, 
suggesting that stabilized SGs are sites of RNA decay (72). The molecular functions of 
these proteins in SG’s remain elusive, however, they are vital to normal stress response. 
 One RNA binding protein that interacts with mutant FUS and whose function in 
the SG-like inclusions has been explored is Pur-alpha (75). Pur-alpha is a single-strand 
DNA binding protein found to localize to SGs when FUS is mutated (75, 76). In cells 
expressing mutant FUS, Pur-alpha overexpression has been demonstrated to play a 
protective role by preventing FUS’ cytoplasmic mis-localization to SGs, thus preventing 
the formation of large inclusion bodies and toxicity (75).  
 As SG formation is thought to be a precursor event to inclusion formation, more in-
depth studies must be performed. A more complete understanding of the interaction mutant 
FUS has with proteins and RNAs localized in SG-like inclusion bodies will illustrate the 
proteins whose function is most impacted by FUS mutations (11, 77).  
 Regulation of RNA Stability 
A burgeoning avenue of research delving further into FUS’ cytoplasmic function is its role 
in managing mRNA stability. Two different mechanisms have arisen to be controlled by 
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FUS to influence the stability of select RNA species: miRNA targeting and Nonsense 
Mediated Decay (NMD).  
 FUS has been established to control miRNA biogenesis for mRNAs required in 
neuronal development and activity through recruitment and loading of Drosha onto pri-
miRNA upon transcription (78). Drosha is a critical enzyme in the miRNA biogenesis 
pathway required to cleave pri-miRNA to pre-miRNA (79). Upon FUS knockdown, the 
levels of miR-9, miR-125b, and miR-132 are all down-regulated. Loss of these miRNA 
species is thought to be due to defective processing of pri-mRNA due to FUS KO. These 
miRNA species have a key role in neuronal function, differentiation, and synaptogenesis, 
respectively (78). Loss of these miRNA results in toxic increases of neuronal proteins. 
 Mutations in FUS, specifically FUS P525L and equivalents, can result in severe 
disturbances in levels of the miRNA landscape due to their exclusion from the nucleus. For 
example, mutations result in upregulation of brain-specific miR-409-3p and miR-495-3p 
(80). Upregulation of these miRNAs is related to a number of neurodevelopmental 
disorders involved down-regulation of Gria2, a subunit of the AMPA receptor. Loss of this 
subunit results in excitotoxic events leading to defective Ca2+ regulation (80). miRNA 
species can also participate in the autoregulatory loops of many RNA binding proteins (81). 
In spinal motor neurons of ALS patients, miR-b2122 expression is depressed and thought 
to regulate TDP-43, FUS/TLS and RGNEF (81). Down-regulation of this miRNA in 
sporadic ALS patients may result in toxic overexpression of these proteins 
 In addition to regulating mRNA levels through miRNA binding and silencing, 
NMD has been identified to play an important role in influencing neurotoxicity in FUS 
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models. In early yeast studies, it was demonstrated that overexpression of UPF1 rescued 
mutant FUS toxicity (82). Further confirmation of NMD’s importance in mediating 
neuronal toxicity was demonstrated in a mouse neuronal model of ALS, where 
overexpression of UPF1 within a particular range, was neuroprotective (83). A deeper 
understanding of how NMD participates in regulation of mRNA stability will be a 
fascinating avenue of study for the ALS field. Research of this pathway in relation to FUS 
ALS may provide many links to other molecular mechanisms thoroughly researched by the 
field, including mRNA splicing and protein translation.  
1.6 Study Rationale and Overview  
 A well-defined molecular mechanism driving FUS ALS remains elusive. We aimed 
to demonstrate a novel mechanism that explored reported defects in RNA metabolism and 
to understand how they are related to the FUS inclusions. Proteins localized to the mutant 
inclusions had not been identified or characterized. It had been widely speculated that 
mutant FUS inclusions are stalled and/ or ultra-stable stress granules, however, a functional 
consequence of their stasis has not been ascribed to them. Additionally, early studies began 
to illustrate a link between FUS and protein translation. Until 2018, however, no efforts 
had been made in the field to further explore protein translation in ALS or its relationship 
with the mutant FUS inclusion. Overall, our goal was to understand the role mutant FUS 
inclusions play in protein translation and mRNA stability. 
 To address this, we designed two exploratory mass spectrometry studies to first 
characterize the mutant FUS inclusions: 1) to examine direct FUS interactors dependent 
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and independent of RNA binding and 2) proteins exclusively associated with the inclusion. 
These studies illustrated the link between mRNA stability, regulation of stress granule 
dynamics, and protein translation. From these data we proposed two hypotheses: 
1. FUS mutations sequester stress granule proteins in inclusion bodies, impairing their 
function. 
2. FUS inclusions are sites of stalled or terminated translation complexes and mRNA 
degradation by NMD. 
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Figure 1.1 FUS Domain Structure 
RGG, Arginine/glycine-rich region; RRM, RNA recognition motif; ZnF, zinc finger 
domain; NLS, nuclear localization sequence. R495X, R521G, P525L, and P525R are 
naturally occurring ALS mutations. 
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Figure 1.2 FUS Nuclear Functions 
FUS binds transcriptionally active DNA directly, as well as on the C-terminal domain of 
RNAP2. When bound to RNAP2, FUS functions to prevent phosphorylation of Ser 2, 
preventing premature termination of transcription. FUS also binds pre-mRNA, facilitating 
formation of U1snRNP and SMN spliceosomal complexes. After splicing is complete, FUS  
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Figure 1.2 Continued 
is exported from the nucleus on mRNA, into the cytoplasm. FUS dissociates from the 
mRNA, binds TNPO1, and is shuttled back into the nucleus.  
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Figure 1.3 FUS' Cytoplasmic Function 
FUS has several cytoplasmic functions related to maintenance and regulation of mRNA 
stability, and protein translation. FUS plays a role in stress granule dynamics, allowing for  
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Figure 1.3 Continued 
disassembly of the temporary structures once acute stress is resolved. FUS also plays an 
elusive role in regulation of translation and axonal protein biosynthesis. Additionally, FUS 
aids in preventing miRNA decay of cytosolic transcripts, facilitating expression of specific 
genes. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell Culture, Plasmids, and Transfection 
 The HEK293T (293T) and N2a cells were cultured in Dulbecco's Modified Eagle's 
Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum and penicillin-streptomycin 
at 37 °C in 5% CO2/95% air. The SH-SY5Y cells were cultured in a 1:1 mixture of 
Dulbecco's Modified Eagle's Medium/F-12 Ham (Sigma-Aldrich, D8437) with 10% fetal 
bovine serum and penicillin-streptomycin at 37 °C in 5% CO2/95% air. The 293T cells 
were transfected with Polyethylenimine “Max” (Polysciences, Inc.). The SH-SY5Y and 
N2a cells were transfected with Lipofectamine 2000 (Life Technologies, 11668). The 
pCMV10 3X FLAG FUS and pEGFP-C3 FUS plasmids used were created for previous 
studies (72). The Polio IRES luciferase translation reporter construct was a generous gift 
from Dr. Tianyan Gao (84). βWT, β39, GPX-1 WT, and GPX-1 PTC NMD reporters were 
a gift from Dr. Jens Lykke-Andersen.  
2.2 Culture and Transfection of Primary Cortical Neurons 
 The mouse primary cortical neuron cultures were prepared as reported (85). Briefly, 
neonatal mouse pups (strain C57BL/6, Jackson Laboratory) were sacrificed via 
decapitation within 24 h of birth. The cells were maintained in Neurobasal Medium (Life 
Technologies, 21103049) with B27 supplement (Life Technologies, 17504044), l-
glutamine and penicillin/streptomycin. Neurons were dissociated from glial cells using 
pipette lavage after incubation with trypsin. The cells were treated with 5-Fluoro-2′-
deoxyuridine (Sigma-Aldrich, F0503). Fourteen days after 5-Fluoro-2′-deoxyuridine 
treatment, the primary neurons were transfected with EGFP-tagged WT or P525L mutant 
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FUS expression constructs using Lipofectamine 2000 (Life Technologies, 11668). The 
primary neurons were fixed 48 h post-transfection for immunofluorescence. 
2.3 GST-FUS Pull-Downs 
 The GST-FUS pull-downs were performed similarly as reported before (72). 
Briefly, the wild type, R521G or P525L mutant human FUS coding sequences were 
inserted into the pEBG glutathione S-transferase (GST) fusion vector (86) using 
the BamHI and KpnI sites. pEBG was a gift from Dr. David Baltimore (Addgene plasmid 
# 22227). 293T cells were transfected with the GST-FUS constructs. Two days post-
transfection, cell lysates were prepared in 1 × RIPA buffer (Millipore, 20-188) 
supplemented with protease inhibitor cocktail (Sigma, P-8340, 1:500) and 1 mM sodium 
orthovanadate with syringe homogenization. The lysates were pre-cleared with Sepharose 
CL-4B (Sigma, CL4B200), then subjected to overnight pull-down with Glutathione 
Sepharose 4B (GE Healthcare, 17-0756-01). Where indicated, a cocktail of RNase A and 
RNase T1 (Life Technologies, AM2286) was added to the pre-cleared lysates before the 
pull-down at 1:100 dilution. The bound proteins were eluted by boiling with Laemmli 
sample buffer (Bio-Rad, 161-0737). 
2.4 Immunoprecipitation 
 Cellular extracts of SH-SY5Y or N2a cells were prepared in 1 × RIPA buffer 
(Millipore, 20-188) supplemented with protease inhibitor cocktail (Sigma, P-8340, 1:500) 
and 1 mM sodium orthovanadate with syringe homogenization. The cellular lysates were 
first pre-cleared with Protein G UltraLink Resin (Thermo Scientific Pierce, 53126), then 
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incubated with antibody against bait protein (Santa Cruz, sc-47711) and Protein G 
UltraLink Resin overnight. The negative control immunoprecipitation antibody was mouse 
anti-HA (Santa Cruz, sc-7392) or normal goat serum. The bound proteins were eluted by 
boiling with Laemmli sample buffer (Bio-Rad, 161-0737) or eluted using FLAG peptide.  
2.5 Proteomic identification of FUS interaction partners 
 The proteins eluted from the Glutathione Sepharose 4B beads were resolved by 
denaturing polyacrylamide gel electrophoresis (SDS-PAGE) on 4–15% gradient gel, 
followed by staining with Sypro Ruby protein gel stain (Molecular Probes, S-12000). Each 
lane was cut into 20 slices of equal size and each slice was subjected to in-gel trypsin 
digestion (87). The resulting tryptic peptides were extracted and subjected to liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) using an LTQ Orbitrap Velos 
mass spectrometer (Thermo Scientific). The LC-MS/MS results were processed with a 
local Mascot server (version 2.3, Matrix Science) for protein identification including 
methionine oxidation and cysteine carbamidomethylation as allowed side chain 
modifications. The LC-MS/MS data of the 20 slices were combined for protein 
identification using the MASCOT algorithm. False discovery rate of 1% was used in decoy 
search for the high-confidence peptides. Proteins with a score of at least 30 for single high-
confidence peptides were considered positive identifications. MS/MS spectra of high-
confidence peptides with scores lower than 50 were manually inspected and confirmed. 
UniProt protein names and identifier numbers are used throughout this work (88). 
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2.6 Western Blot 
 The nitrocellulose membranes were blocked, and antibodies were applied in 5% 
milk in TRIS-buffered saline/Tween-20 (TBST, 0.1 M TRIS-HCl, 0.9% [w/v] NaCl, 0.1% 
[v/v] Tween-20, pH 7.5). The antibodies used were anti-NF45/ILF2 (Bethyl, A303-147A-
M), anti-DHX9 (Bethyl, A300-855A-M), anti-Matrin-3 (Bethyl, A300-591A-M), anti-
hnRNPA1 (Novus, NB100-672), anti-Caprin-1 (Proteintech, 15112-1-AP), anti-GST 
(Santa Cruz, sc-459), anti-DDX3X (Sigma, HPA001648), anti-actin (Santa Cruz, sc-1616), 
anti-FLAG (Sigma, A8592., anti-eIF4A1 (Cell Signaling, 2490), anti-eIF4G (Cell 
Signaling, 2469), anti-eIF4E (Cell Signaling, 9742), anti-eIF3 (Santa Cruz, sc-74507), anti-
eIF4A3 (ProteinTech, 17504-1-AP), anti-RPS6 (Cell Signaling, 2217), anti-G3BP1 
(ProteinTech, 13051- 2-AP), anti-RPL7a (Cell Signaling, 2415), anti-K48 TUBE (Tandem 
Ubiquitin Binding Entity, LifeSensors, UM305), anti-K63 TUBE (LifeSensors, UM304), 
anti-pan ubiquitin (Santa Cruz, sc8017), anti-HA (Santa Cruz, sc-805), anti-UPF1 (Bethyl, 
A300-038A), anti-phospho Ser/Thr 4 ATM/ AMR substrate (i.e. p-S/T, Cell Signaling, 
2851), anti- phospho UPF1 S1089 (Millipore 07-1015), anti-PABP1 (Santa Cruz, sc-
32318), anti-eRF3b (Santa Cruz, 515615), anti-BrdU (Abcam, ab6326), anti-p62 
(ProteinTech, 18420-1-AP) anti-Actin (Santa Cruz, sc-81178), antiGAPDH (Santa Cruz, 
sc-32233), anti-puromycin (Millipore, MABE343), anti-UPF3a (Proteintech, 17114-1-
AP), anti-XRN1 (Bethyl, A300-443A-M), Anti-UPF3b (Invitrogen, PA5- 51652), anti-
SMG6 (Abcam, ab87539), anti-SMG1 (Abcam, ab30916), anti-SMG5 (ThermoFisher, 
PA5-44295), anti-SMG7 (ThermoFisher, PA5-38140), anti-RNPS1 (PA5- 35967), and 
anti-FUS (Santa Cruz, sc-47711). The immunoblotting images were acquired with the 
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Chemidoc MP Imaging System (Bio-Rad) and quantified with the Image Lab software 
(Bio-Rad). 
2.7 Immunofluorescence microscopy 
 SH-SY5Y or N2a cells were seeded on gelatin-treated glass coverslips and 
transfected with EGFP-tagged FUS constructs (72). After 48 hours, the cells were fixed in 
4% (w/v) paraformaldehyde in 1 × PBS, permeabilized with 0.25% (v/v) Triton X- 100 in 
1 × PBS and blocked with 10% (w/v) bovine serum albumin (BSA) in 1 × PBS. The slides 
were incubated with primary antibodies diluted in 3% (w/v) BSA/1 × PBS. The primary 
antibodies were the same as those used for immunoblotting. The secondary antibodies were 
Alexa Fluor 568 Donkey Anti-Rabbit IgG or Alexa Fluor 568 Donkey Anti-Mouse IgG 
(Life Technologies, A10042 and A10037, respectively). The nuclei were visualized with 
4′,6-diamidino-2-phenylindole (DAPI). The coverslips were mounted on glass slides with 
Vectashield Mounting Medium (Vector Laboratories, H-1000-10). Confocal microscopic 
images were acquired using a Nikon A1 confocal microscope with a 60 × objective. 
2.8 Patient Skin Fibroblast Culture 
 Human skin fibroblasts were prepared and maintained as previously described (89). 
Briefly, a skin punch was obtained from consenting patients with symptomatic ALS and 
family members free of disease. Brief information on the subjects is shown below. The 
biopsies were washed in phosphate-buffered saline (PBS), minced, and incubated in 
fibroblast growth media (MEM [Sigma-Aldrich, M5650]) supplemented with 20% FBS, 2 
mM L-glutamine, 100 unit/mL penicillin, and 100 μg/mL streptomycin) at 37°C under 5% 
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3 CO2/95% air. Informed consent was obtained from all participants who donated a skin 
biopsy. Information on the 11 subjects (five patients with familial ALS with the R521G 
mutation, one patient with the P525R mutation, and five healthy controls with WT FUS) 
is shown in Table 2.1. The study was approved by the Institutional Review Board of the 
University of Kentucky.  
2.9 Membrane Filtration 
 N2a cells were transfected with 3X FLAG FUS construct. After 48 hours, the cells 
were lysed in either RIPA buffer (Millipore, 20-188) or a hypotonic lysis buffer (20 mM 
HEPES (pH 7.4), 2 mM EGTA, 2 mM MgCl2: Cold Spring Harbor Laboratory). The 
lysates were centrifuged at 20,000xg and the supernatant removed. The protein 
concentrations were measured. Hydrophilic PVDF membranes (ThermoFisher, 88518) 
were applied to the BioRad Dot Blot Filtration Manifold (1706545) and the wells were 
rinsed with ACN. 100ug of protein lysate was applied to each well and vacuum pressure 
was applied. The wells were washed with lysis buffer three times and the membrane 
removed for either western blotting using anti-FLAG antibody (Sigma-Aldrich, A8592) or 
mass spectrometric analysis.  
2.10 Native Gel Electrophoresis 
 Cells were harvested with RPIA or hypotonic low detergent lysis buffer and 
homogenized by either passing through a 23-gauge needle. Cell lysates were centrifuged 
at 20,000 × g at 4 °C for 10 min. The supernatant (50 μL) was taken out and mixed with 
10 μL 6× loading buffer (350 mM Tris·Cl, pH 6.8, 30% (vol/vol) glycerol, 0.24% SDS, 
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0.02% bromophenol blue). Samples were loaded on a 6% (wt/vol) polyacrylamide gel 
soaked in detergent-free running buffer (25 mM Tris, 192 mM glycine). A total of 75 V 
was applied for stacking and 120 V was applied for separating. Subsequently, the gel was 
incubated with transfer buffer (25 mM Tris, 192 mM glycine, 10% (vol/vol) methanol) 
supplemented with 0.25% 5 SDS at 70 °C for 10 min. After the denaturation step, the gel 
was ready for transferring and Western blotting following the same procedure as described 
earlier.  
2.11 Proteomic identification of proteins captured by membrane filtration 
 The membrane dots were subjected to trypsin digestion and the resulting tryptic 
peptides were subjected to liquid chromatography-tandem mass spectrometry (LC-
MS/MS) as previously described in (2.V). False discovery rate of 1% was used in decoy 
search for the high-confidence peptides. Proteins were considered significant 
identifications if they met the following criteria: 1) the proteins had at least one unique 
peptide; 2) the identified protein had a score above 36; 3) they were unique in any of the 
samples.  
2.12 Enrichment Analysis of roteins captured by membrane filtration 
 Proteins identified in FUS inclusions were subjected to functional enrichment 
analysis using an integrative online enrichment analysis tool Enrichr (90, 91) that allows 
the examination of protein lists using a variety of libraries. Using the mouse exome as the 
universe for the enrichment, proteins were analyzed based on their function using the GO: 
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Molecular Function database (92, 93) and their disease relevance using the DISEASES 
database (94).  
2.13 RNA FISH 
 N2a cells or primary neurons were transfected with EGFP-C3 FUS constructs and 
fixed with 4% w/v paraformaldehyde (Pierce, 28908) 48 hours post transfection. Cells were 
then permeabilized with 0.25% (v/v) Triton X-100 in 2x saline-sodium citrate (SSC) buffer 
(Invitrogen, AM9763) and blocked in Salmon sperm DNA in 2X SSC for one hour. Slides 
were incubated with 1ug/uL stock diluted 1:1000 oligo d(T)21 or anti-FUS (exon 4) probe 
for one hour at 37°C and then washed three times with 4x SSC and 3x with 2x SSC. The 
anti-FUS probe was generated by amplifying FUS exon 4 mRNA and was inserted into a 
pCRII-TOPO vector (ThermoFisher, 452640) for in vitro transcription. The anti-FUS 
probe was made using ThermoFisher FISH Tag RNA Multicolor Kit nuclei (ThermoFisher, 
F32956). Nuclei were visualized using DAPI. Coverslips were mounted on glass slides 
using Vectashied Mounting Media (Vector Laboratories, H-1000-10) and confocal images 
were acquired using a Nikon A1 confocal microscope.  
2.14 RNA Immunoprecipitation followed by qPCR 
 To measure mRNA bound with protein of interest, immunoprecipitation was 
performed as described above. One difference is that SUPERaseIn (ThermoScientific; 
AM2696) was included in the RIPA buffer along with protease inhibitors. After 
immunoprecipitation, the bead slurry was split into two aliquots. One was for protein 
elution and immunoblotting as described above. The other was transferred to a new tube 
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for RNA isolation using Trizol reagent per manufacturer instructions. Equal amounts of 
isolated RNA were used for cDNA synthesis using the SuperScript III First Strand 
Synthesis System (ThermoScientific; 18080051). qPCR was performed using SYBR Green 
(ThermoScientific; 4309155) and quantitative results were obtained using the ∆∆CT 
method. Primers used in this study are listed in Table 2.2.  
2.15 Protein Translation Assays 
 For the Cap-dependent translation reporter assay: Protein translation efficiency was 
measured using a cap-dependent translation reporter assay as previously described (84). 
Briefly, N2a cells were transfected with the reporter plasmid along with empty vector, WT 
or mutant FUS. After 48 hours, cells were harvested and lysed followed with luminescence 
measurement using the Promega luciferase assay kit (Promega, E2940). The cap-dependent 
Renilla luciferase activity was compared to that with empty vector. The Firefly luciferase 
activity was used as a transfection control.  
 For the 35S-Met incorporation assay: N2a cells were transfected with 3X FLAG 
FUS and after 48 hours incubated with 1µM puromycin (P8833, Sigma) for thirty minutes. 
Cells were washed with PBS to remove residual puromycin. Cells were lysed using 1x 
RIPA buffer and centrifuged at 1,000xg. Lysates where then run on an SDS-PAGE gel and 
transferred to a nitrocellulose membrane for western blotting with anti-puromycin antibody 
(Millipore, MABE343). Puromycin staining in lanes was measured using Bio-Rad imaging 
software and normalized to actin.  
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 For the SUnSET Assay: N2a cells were transfected with 3X FLAG FUS and after 
48 hours and lysed in water. Lysates were syringe homogenized and centrifuged at 1,000xg 
to remove cellular debris. Lysate was then incubated with rabbit reticulocyte lysate, ATP, 
and 35SMethionine. The mixture was incubated at 37°C for one hour. We then precipitated 
the protein to remove excess 35S-Methionine and took the beta particle count on the 
scintillation counter.  
2.16 7’ Methyl-guanosine Pulldown 
 N2a cells were transfected with 3X FLAG FUS and after 48 hours, lysed using 1x 
RIPA buffer. The lysate was spun at 1,000xg and precleared using Sepharose beads 
(Sigma-Aldrich, CL4B200). After preclearing, the lysates were incubated with 7’ Methyl-
guanosine residues conjugated to agarose beads and incubated at 4°C overnight 
(JenaBiosciences, AC-155S). Beads were washed three times and the bound proteins were 
eluted by boiling with Laemmli sample buffer (Bio-Rad, 161-0737). Eluates were run on 
SDSPAGE gels.  
2.17 Bromouridine Immunoprecipitation 
 N2a cells were transfected with 3X FLAG FUS and after 24 hours incubated with 
1µM bromouridine (BrU) (Sigma Aldrich, 850187) for 24 hours. Cells were washed with 
PBS to remove residual BrU. Protein and RNA were crosslinked using a StrataLink 
Crosslinker (254nm, 1200kJ). Cells were lysed using 1x RIPA buffer and centrifuged at 
1,000xg. Crosslinked lysate was incubated with anti-bromodeoxyuridine to 
immunoprecipitate RNA and Protein G UltraLink Resin (Thermo Scientific Pierce, 53126) 
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overnight at 4°C. Beads were washed three times and the bound proteins were eluted by 
boiling with Laemmli sample buffer (Bio-Rad, 161-0737). Eluates were run on SDS-PAGE 
gels followed by immunoblotting.  
2.18 NMD Activity Assays 
 For the NMD Reporter Assay: N2a cells are co-transfected with 3X FLAG FUS 
and pcDNA NMD reporter (β-globin WT, β-globin PTC39, GPX-1 WT, GPX-1 PTC) that 
were previously reported (10). Cells were harvested 48 hours after transfection and RNA 
was extracted using Trizol, purified of plasmid using RQ1 RNase free DNase (Promega, 
M6101), purified again using a phenol/chlorophorm method, and subjected to qPCR.  
 For the Endogenous NMD substrate qPCR: Trizol reagent was used to isolate RNA 
from N2a cells or fibroblasts per manufacturer instructions. Equal amounts of isolated 
RNA were used for cDNA synthesis using the SuperScript III First Strand Synthesis 
System (ThermoScientific; 18080051). qPCR was performed using SYBR Green 
(ThermoScientific; 4309155) and quantitative results were obtained using the ∆∆CT 
method.  
2.19 RNA Stability Assay 
 N2a cells were transfected with 3x FLAG FUS constructs. After 48 hours, cells 
were treated with 1 µM ActinomycinD (Sigma-Aldrich; A1410) for two or four hours, or 
DMSO for four hours for experiments examining UPF1, UPF3b, and UPF3a stability. The 
same concentration of ActinomycinD was used for examining the stability of ATF3, ATF4, 
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TBL2, and CyclophilinD, but a time course of one, two, or three hours, or three hours with 
DMSO was used. RNA was isolated using Trizol as described above and subject to qPCR.  
2.20 Statistics 
 Western blot band and lane quantification was done using BioRad Imaging 
Software. In assays using patient fibroblasts, mutant band intensity ratios were pooled into 
one group. ANOVA with post hoc Tukey HSD (honest significant difference) test was used 
to determine p values for multiple pair-wise comparisons. Student’s t test (two-tailed 
distribution, two-sample unequal variance) was used to determine p values for simple pair-
wise comparison. Authors were not blinded to control or experimental groups. All 
experiments, except immunofluorescent assay, were done in triplicate.  
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Table 2.1 Patient Fibroblasts 
ID Group ID Group FUS 
Genotype 
Gender Age at Biopsy 
017 Control WT F 43 
010 Control WT F 36 
012 Control WT F 63 
008 Control WT F 24 
089 Control WT M 20 
091 ALS R521G F 31 
001 ALS R521G M 56 
014 ALS R521G M 42 
007 ALS R521G M 58 
018 ALS R521G F 40 
090 ALS P525R F 26 
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Table 2.2 List of qPCR Primers 
GENE FORWARD REVERSE 
MOUSE UPF1 AGAGCAGCCTGAAGGACATC TCCAGCTTGTTGATCTGCTG 
MOUSE 
UPF3B 
GAGTGACCCTGTTTACGCC TCAAAGTGGGAGGTAATCTTCG 
MOUSE 
UPF3A 
ATGCGCTCGGAAGAGG CTACTGGGCCTTGTGTCC 
MOUSE FUS 
(EXON 4) 
CCAGGGATATGGTTCCACTG CTGCTAGGAGCTGGCTGTTG 
MOUSE 
ATF3 
ATAAACACCTCTGCCATCGG GCCTCCTTTTCCTCTCATCTTC 
MOUSE 
ATF4 
GGTTCTCCAGCGACAAGG GCATCGAAGTCAAACTCTTTCAG 
MOUSE 
TBL2 
TCCACGATCAACACTAACCAG CGAAACAGACCTCCCAGAC 
MOUSE 
CYCLOPHIIN 
D 
CCCTCCAACTCCAAGAACC TTCTCCTGTACACAACGCAC 
MOUSE 
RPL13A 
CTGTGAAGGCATCAACATTTCTG GACCACCATCCGCTTTTTCTT 
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HUMAN 
UPF1 
AGAGCAGCCTCAAGGACATC TCCAGCTTGTTGATCTGCTG 
HUMAN 
UPF3B 
GTTCATATTCCCGTTCCCTCTC TGCCCAAGCGTTCTGATAG 
HUMAN 
UPF3A 
TCCAGCTTGTTGATCTGCTG GGCAATCTTCTGGAATGGAG 
HUMAN 
ATF3 
GTTTGCCATCCAGAACAAGC GTCGCCTCTTTTTCCTTTCATC 
HUMAN 
ATF4 
CCAAGCACTTCAAACCTCATG ATCCATTTTCTCCAACATCCAATC 
HUMAN 
TBL2 
AATATCAGCGGATTCGGAAGG ACAGGTAGCCAGGTATTTGC 
HUMAN B-
ACTIN 
AGAGCTACGAGCTGCCTGAC GGATGTCCACGTCACACTTC 
NMD 
REPORTER: 
HUMAN B-
GLOBIN 
AGGAGAAGTCTGCCGTTACT GAGCCAGGCCATCACTAAAG 
NMD 
REPORTER: 
RAT GPX-1 
GGGACTACACCGAAATGAATGA GGACAGCAGGGCTTCTATATC 
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CHAPTER 3. PROTEOMIC ANALYSIS OF FUS INTERACTING PROTEINS PROVIDES INSIGHTS 
INTO FUS FUNCTION AND ITS ROLE IN ALS 
Modified from the manuscript “Proteomic analysis of FUS interacting proteins provides 
insights into FUS function and its role in ALS”, published in the Biochimica et 
biophysica acta. 2016;1862(10):2004-14. Epub 2016/07/28. doi: 
10.1016/j.bbadis.2016.07.015. PubMed PMID: 27460707; PMCID: PMC5055831. The 
introduction was simplified for fluidity and experiments not performed by M.K were 
excluded. 
3.1 Introduction 
 Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a 
progressive and ultimately fatal neurodegenerative disease of the upper and lower motor 
neurons of the brain and spinal cord. At any given time, approximately 30,000 people in 
the United States are living with the disease (95). There is currently no cure available for 
those afflicted (96). General symptoms of ALS are muscle weakness and wasting triggered 
by the degeneration of motor neurons. In order to develop effective preventive measures 
or cures, we have to gain a better understanding of the molecular etiology of the disease. 
 Approximately 10% of the ALS cases are familial (fALS) and caused by heritable 
mutations in a number of different genes. A subset of fALS cases is caused by autosomal 
dominant mutations in the gene encoding Fused in Sarcoma/Translocated in Liposarcoma 
(FUS/TLS) (2, 3). FUS mutations were also identified in a subset of the sporadic ALS 
(sALS) cases (97-99). In most tissues, FUS is predominantly localized to the nucleus with 
a notable cytoplasmic presence in neurons (100). FUS has several known functions in 
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multiple cellular pathways. FUS binds RNA and shuttles between the nucleus and the 
cytoplasm, participating in nucleo-cytoplasmic RNA shuttling (101). FUS also plays roles 
in DNA repair (102-104), transcription (13, 20, 33, 61, 105-111), RNA splicing (20, 112, 
113), dendritic RNA transport (114-116),  and miRNA biogenesis and function (78, 117). 
However, the physiological functions of FUS are still not fully understood. The ALS-
related FUS mutations cause varied degrees of cytoplasmic mis-localization of FUS and 
the formation of stress granule-like structures (12, 62, 63, 72). In a subset of frontotemporal 
dementia cases, pathological cytoplasmic mis-localization of FUS was found without FUS 
mutations (118, 119). The depletion of FUS in the nucleus likely results in partial loss of 
its nuclear function(s). In addition, its cytoplasmic accumulation and the formation of stress 
granule-like structures and other ribonucleoprotein complexes might lead to a gained 
toxicity phenotype. These loss-of-function and gain-of-function/gain-of-toxicity 
mechanisms are both plausible and are not mutually exclusive (40, 120). 
 To gain insight into the normal functions of FUS and the pathogenesis caused by 
its mutations, we performed GST-FUS pull-downs from human cells expressing wild-type 
and R521G mutant FUS, followed by proteomic identification of the FUS interacting 
partners. In addition to previously reported interacting proteins, many novel interacting 
partners were identified in this study, including members of the spliceosome, IMP1-
dependent ribonucleoprotein particles, transport RNA granules and stress granules. Many 
of the identified interacting partners are shared between two or more of these 
ribonucleoprotein particles. We selected a set of the identified FUS interacting partners 
that participate in a wide range of functions for further analysis. We validated the 
interaction of FUS with the selected partners and determined the RNA dependence of those 
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interactions. We found that the interactions of FUS with some partners were enhanced, 
whereas with others were partly or completely abrogated by RNase digestion. Importantly, 
we found that FUS interacted with hnRNPA1 and Matrin-3, proteins whose mutations were 
also identified to cause familial ALS (121, 122). We found that ALS mutants of FUS co-
localized with Caprin-1, DDX3X, and DHX9 in cytoplasmic inclusions that could lead to 
the mis-regulation of their respective pathways, providing further clues to the mechanism 
of ALS pathogenesis. 
3.2 Results 
 Identification of FUS interaction partners 
 We generated GST-FUS expression constructs using the pEBG vector that 
expresses the glutathione S-transferase (GST) gene of Schistosoma japonicum under 
control of the human EF-1α promoter (86). We performed GST pull-downs from human 
HEK293T (293T) cells transfected with wild-type (WT) or R521G mutant GST-FUS or 
the GST vector. The GST-FUS pull-downs were performed both in the presence and 
absence of added RNase in the cellular lysates. SDS-PAGE revealed major banding pattern 
differences between the GST vector control and the GST-FUS lanes (Fig. 3.1). Proteins 
that were identified in the vector lane (several human glutathione S-transferases and other 
proteins) and common contaminants such as keratin, heat shock proteins and abundant 
cytoskeletal components were excluded from the analysis of the GST-FUS lanes. It is noted 
that no endogenous FUS was identified in the GST vector control lane, suggesting that the 
endogenous FUS did not bind non-specifically to the Glutathione Sepharose 4B beads. 
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 We identified the FUS interacting proteins using the Mascot software (Matrix 
Science). Mascot uses probability-based scoring to judge whether identifications are 
significant. The peptide score shows the probability of whether the observed match is a 
random event. Scores are reported as −10 × log10(P), where P is the probability. For 
example, a Mascot score of 30 means that the probability of a peptide identification being 
a random event is 0.001. The protein score is calculated from the scores of the individual 
peptides. A total of 112 proteins were identified as FUS-interacting partners in this study. 
Among them, 70 were non-ribosomal proteins (Supplemental Table 3.1) and 42 were 
ribosomal proteins (Supplemental Table 3.2). The count of the peptides identified at high 
confidence level (false discovery rate < 1% in decoy search) is shown in the tables, and 
only proteins identified with a compounded score of 30 or higher are listed. The MS/MS 
spectra of high-confidence peptides with scores lower than 50 were manually inspected 
and confirmed. Proteins identified with these parameters are considered highly confident 
identifications. 
 Validation and characterization of selected FUS interactions 
 We demonstrated the co-precipitation of endogenous DHX9, Matrin-3, ILF2 and 
hnRNPA1 with endogenous FUS immunoprecipitated from SH-SY5Y cells (Fig. 3.2). We 
also validated the interaction of FUS with endogenous DHX9, Matrin-3, DDX3X, Caprin-
1, ILF2 and hnRNPA1 in 293T cells using GST-FUS pull-down followed by immunoblot 
with specific antibodies (Fig. 3.3A–B, lanes 1 and 3). We determined whether the 
interactions of FUS with the above proteins depended on RNA. Cells were transfected with 
GST vector or GST-tagged WT, R521G or P525L FUS expression constructs and the cell 
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lysates were subjected to GST pull-down either with or without the addition of RNase (Fig 
3.3A). The precipitation of the baits was verified with anti-GST immunoblot (Fig. 3.3B). 
The immunoblots of the co-precipitating proteins were quantified from three independent 
experiments (Fig. 3.3C). The binding of FUS to its interaction partners was differentially 
affected by RNase treatment (Fig. 3..3A and C). The amounts of the co-precipitated Matrin-
3 and that of the RNA helicases DHX9 and DDX3X were significantly enhanced by RNase 
treatment. The interactions of FUS with Caprin-1 and ILF2 were weakened, but not fully 
abrogated, by the RNase treatment. The interaction of FUS with hnRNPA1 was entirely 
dependent on RNA, as the RNase treatment completely abolished its interaction with FUS. 
Thus, the interactions of FUS with DHX9, Matrin-3 and DDX3X are likely protein-protein 
interactions that do not require RNA, whereas the interactions with Caprin-1, ILF2, and 
hnRNPA1 are partly or fully RNA-dependent. 
 Co-localization of FUS interaction partners with cytoplasmic ALS mutant 
FUS inclusions 
 We tested whether the selected interaction partners co-localized with cytoplasmic 
inclusions of mutant FUS in the SH-SY5Y human neuroblastoma cell line transfected with 
EGFP-tagged WT, R521G or P525L FUS. We found that EGFP-tagged WT FUS localized 
to the nuclei of SH-SY5Y cells. The localization of R521G mutant FUS ranged widely 
from mostly nuclear to mostly cytoplasmic. The localization of P525L FUS was even 
further shifted towards the cytoplasm. Both the R521G and the P525L FUS mutants formed 
cytoplasmic inclusions (Fig. 3.4). The DHX9 protein was primarily localized to the nuclei 
of SH-SY5Y cells sharing a similar distribution pattern with that of nuclear FUS (Fig. 
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3.4A). The expression of both R521G and P525L FUS resulted in the accumulation of 
small amounts of DHX9 in cytoplasmic mutant FUS inclusions (Fig. 3.4A). The DDX3X 
protein was mostly localized to the cytoplasm (Fig. 3.4B). DDX3X was efficiently 
sequestered by the cytoplasmic inclusions of both R521G and P525L mutant FUS (Fig. 
3.4B). We had similar observations with the mostly cytoplasmic CAPR1/Caprin-1. The 
expression of R521G and P525L FUS induced the formation of cytoplasmic Caprin-1-
positive inclusions, most of which co-localized with the mutant FUS inclusions (Fig. 3.4C). 
We also demonstrated the co-localization of DHX9, DDX3X and Caprin-1 with 
cytoplasmic EGFP-P525L mutant FUS inclusions in primary cortical neurons (Fig. 3.5) 
 The co-localization of DHX9, DDX3X and Caprin-1 with mutant FUS inclusions 
was quantified in SH-SY5Y cells transfected with EGFP-tagged P525L mutant FUS in four 
independent experiments, each representing over 400 transfected cells. On average, 24.5% 
of the transfected cells contained cytoplasmic P525L mutant FUS inclusions. DHX9 co-
localized with 89.7%, DDX3X with 97.9%, and Caprin-1 with 88.7% of the cytoplasmic 
P525L mutant FUS inclusions, respectively. 
 The FUS interaction partners Matrin-3 and hnRNPA1 were localized to the nuclei 
of SH-SY5Y cells and were not detected in cytoplasmic mutant FUS inclusions (Fig 3.6A–
B). The ILF2 protein was primarily in the nuclei and was not detected in cytoplasmic 
mutant FUS inclusions, either (Fig. 3.6C). These results suggest that the detected 
complexes of FUS with Matrin-3, hnRNPA1, and ILF2 were likely nuclear that will be 
explored in future studies. 
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 Significantly enriched Gene Ontology (GO) terms among the identified 
FUS interacting partners 
We searched for significantly enriched GO terms for the identified FUS interacting partners 
using the STRING server (http://www.string-db.org/, (123)). The enriched GO Biological 
Processes, Molecular Functions and Cellular Components of FUS interacting partners are 
summarized in (Tables 3.3- 3.5), respectively. The p-values shown in the tables are 
Benjamini-Hochberg corrected p-values for enrichment of the terms in question, 
representing the estimated false discovery rate (124). 
 Based on the GO Biological Processes, the majority of significantly enriched terms 
were related to various aspects of gene expression and RNA metabolism, such as 
chromosomal organization, transcription, RNA splicing, RNA processing, RNA transport, 
translation and RNA stability (Table 3.1). Based on the GO Molecular Functions, the 
majority of the identified FUS interaction partners are RNA and/or DNA binding proteins 
with a considerable enrichment for RNA helicases (Table 3.2). The FUS interacting 
partners CN166, CTR9 and ZN326 represent three of the 21 UniProt entries annotated with 
the significantly enriched GO Molecular Function “RNA polymerase II core binding” 
(Table 3.2). Among the significantly enriched GO Cellular Components were various 
ribonucleoprotein complexes including ribosomes, splicing complexes, the SMN-Sm 
protein complex and cytoplasmic stress granules (SGs). Also enriched were chromosomal 
proteins and components of extracellular exosomes (Table 3.3). 
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 FUS interacts with overlapping ribonucleoprotein complexes 
 Our analysis showed that the majority of the identified non-ribosomal FUS 
interaction partners (Supplemental Table 3.1) are known members of at least one of four 
types of ribonucleoprotein complexes: spliceosomes, IMP1-dependent ribonucleoprotein 
(RNP) granules, transport granules or stress granules (Fig. 3.7). In Fig. 3.7, only the FUS-
interacting ribosomal proteins that were specifically identified as part of the above 
complexes are shown. 
 This study identified the following FUS-interacting proteins that were previously 
identified as spliceosomal components: ROA1/hnRNPA1, ROA2/hnRNPA2B1, 
ROA3/hnRNPA3, HNRPC/hnRNPC, RBMX/hnRNPG, HNRH1/hnRNPH, 
HNRPK/hnRNPK, HNRPM/hnRNPM, HNRPR/hnRNPR, HNRPU/hnRNPU, PABP1, 
RSMB/SNRPB, SMD1, SMD3, RUXE/SNRPE, SF3B1, SF3B3, U520/SNRNP200, 
SK2L2, DDX5 and ZCHC8 (125), and SR140 and SRSF7 (126, 127). In addition, FUS-
interacting proteins are involved in a tRNA splicing ligase complex that is not part of the 
spliceosome: RTCB/HSPC117, CN166/CGI-99 and DDX1 (128). 
 Another group of FUS interacting proteins identified in this study belong to the 
IMP1-dependent mRNP granules. They include: DHX9, HNRPU/hnRNPU, 
NUCL/Nucleolin, PABP1, ILF2, ILF3, HNRPR/hnRNPR, PABP4, ROA1/hnRNPA1, 
ROA2/hnRNPA2B1, RLA0, RS3, RS3a, RS4X, RS6, RS8 (129), as well as 
HNRPK/hnRNPK, ROA3/hnRNPA3, and ELAV1/HuR (130). 
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 The third group of our identified FUS-interacting proteins contains components of 
RNA transporting granules. DDX1, DDX3X, DDX5, RTCB/HSPC117, CN166/CGI-99, 
FMR1, FXR1, RL3, ROA1/hnRNPA1, HNRPU/hnRNPU, and NUCL are components of 
a FUS-positive kinesin-mediated RNA transporting dendritic granule complex (131). 
Moreover, the DHX9, FMR1, HNRPU/hnRNPU, ILF3, NUCL, PABP1, RLA0, RL6, 
RL7A, RL10, RL14, RS2, RS3A, RS6, and RS8 proteins identified in this study were 
reported as components of Staufen-containing transport ribonucleoprotein 
complexes (132, 133). In addition, ROA2/hnRNPA2 (134) and CAPR1/Caprin-
1 (74) were also identified in RNA transport granules. 
 The fourth group among our identified FUS-interacting proteins belongs to stress 
granules. They include ATX2L, CAPR1/Caprin-1, DDX1, DDX3X, DDX6, 
DHX36/RHAU, ELAV1/HuR, FMR1, FXR1, G3BP2, ROA1/hnRNPA1, 
ROA2/hnRNPA2, HNRPK/hnRNPK, ILF3, PABP1, RS3, RS6, RS18, RBP56/TAF15 and 
PABP4 (73, 135). Moreover, the two FUS-interacting proteins DDX6/RCK and MOV10 
are components of processing bodies (P-bodies) (136-138) that functionally interact with 
stress granules (139). NPM, PARP1 and NUCL were identified as part of the SWAP 
complex, a B-cell-specific DNA recombination complex (140). 
 NPM, PARP1 and NUCL were identified as part of the SWAP complex, a B-cell-
specific DNA recombination complex (140). 
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3.3 Discussion 
 Identification and validation of FUS interaction partners 
 We identified 70 non-ribosomal and 42 ribosomal proteins as FUS interaction 
partners in this study (Fig. 3.1 and Fig. 3.6). No endogenous FUS was identified in the 
GST vector control pull-down. Proteins identified in the GST vector control experiment 
were excluded from the analysis of the GST-FUS pull-downs. Most FUS interaction 
partners we identified are known RNA and DNA binding proteins (Table 3.1) involved in 
pathways regulating various aspects of gene expression and RNA metabolism including 
transcription, splicing, RNA processing, RNA stability, RNA transport and translation 
(Table 3.1). Selected interactions were validated by immunoprecipitation and GST pull-
down followed by immunoblotting (Fig. 3.2, Fig. 3.3). Immunostaining followed by 
confocal microscopy showed that the FUS interaction partners DHX9, DDX3X and 
Caprin-1 localized to cytoplasmic FUS inclusions (Fig. 3.4, Fig. 3.5). 
 Our method to generate cellular lysates efficiently extracted not only cytosolic 
proteins but also predominantly nuclear proteins such as WT FUS, DHX9, Matrin-3 and 
hnRNPA1 (Fig. 3.2, Fig. 3.3, Fig. 3.4, Fig. 3.5, and Fig 3.6). In the pull-down studies, we 
detected interactions between proteins mostly residing in different cellular compartments 
such as the interactions between the predominantly nuclear WT FUS and the almost 
exclusively cytoplasmic DDX3X or Caprin-1 (Fig. 3.3, Fig. 3.4, Fig. 3.5). This observation 
demonstrates the significance of examining interacting proteins with imaging techniques 
in cells to determine whether the proteins interact with each other in live cells under 
physiological conditions. 
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 Many FUS interacting partners participate in two or more of the ribonucleoprotein 
complexes shown in Fig. 3.7. Ribonucleoprotein complexes are highly dynamic structures 
that can exchange components and transition from one kind of complex to another. It is 
conceivable that FUS cycles between different molecular complexes and ribonucleoprotein 
granules depending on a number of cellular influences including subcellular localization 
and stress conditions. 
 The RNA dependence of FUS interactions 
 The identified interactions were differentially impacted by the introduction of 
RNase into the pull-down mixtures. Whereas the interactions of FUS with DHX9, Matrin-
3 and DDX3X are likely protein-protein interactions that were enhanced by RNase 
digestion, the interactions of FUS with CAPR1, ILF2, and hnRNPA1 were partly or fully 
RNA-dependent (Fig. 3.3). It is likely that FUS molecules cycle between RNA-bound and 
RNA-unbound states as they interact with successive target RNA molecules. Our results 
showed that FUS displayed differential affinities to its protein interacting partners in the 
RNA bound and RNA-unbound states, suggesting that the protein interacting partners of 
FUS likely also change during the RNA binding cycles. RNase treatment can free up 
molecular surfaces for protein-protein interactions otherwise occupied by RNA. 
Alternatively, the RNA-bound and unbound states of FUS might assume different 
conformations, regulating the preference of FUS to varied interaction partners. 
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 The interaction of FUS with the ALS-related proteins Matrin-3 and 
hnRNPA1 
 We discovered that FUS interacted with MATR3/Matrin-3 and ROA1/hnRNPA1 
(Figs. 3.2, 3.3 and Supplemental Table 3.1), proteins whose mutations were also identified 
to cause familial ALS (121, 122). This suggests that FUS might be involved in common 
pathogenic pathways with Matrin-3 and hnRNPA1. There are intriguing differences 
between these complexes, though. The interaction between FUS and Matrin-3 was 
enhanced by RNase treatment, whereas the FUS-hnRNPA1 interaction was entirely 
dependent on RNA (Fig. 3.3). It is relevant that hnRNPA1 was reported to localize to stress 
granules (121, 141) similarly to FUS (10, 12, 62, 63, 72, 100, 142). The analysis of the role 
of the FUS-Matrin-3 and FUS-hnRNPA1 complexes in ALS pathogenesis is underway. 
 FUS interacts with regulators of protein phosphorylation 
 We identified the FUS interaction partners KHDR1, ILF2, ILF3 and RBMX/ 
hnRNPG that were previously reported to be in a complex with the serine/threonine-protein 
phosphatase PP1-α catalytic subunit PP1A (Fig. 3.7) (143). The ILF2 and ILF3 proteins 
were also reported to interact with and regulate the DNA-dependent protein kinase (DNA-
PK) (144). The phosphorylation of FUS by DNA-PK was recently reported (145). Our 
results suggest that the KHDR1/ILF2/ ILF3/RBMX complex might regulate FUS 
phosphorylation. FUS also interacted with CSK21, the catalytic alpha subunit of casein 
kinase II and the serine/threonine-protein kinase Nek10. The casein kinase II-mediated 
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FUS phosphorylation and its functional relevance are currently being investigated in our 
laboratory. 
 Loss of nuclear FUS functions due to ALS mutations 
 We found that FUS interacted with numerous proteins that regulate nuclear 
processes. Twenty-six of the FUS interacting partners we isolated were annotated as 
regulators of DNA-templated transcription (Table 3.1). Twenty-three of the FUS 
interaction partners we identified are known spliceosomal components (Table 3.1, Fig 3.7). 
The splicing-related “Survival motor neuron” (SMN)-Sm protein complex was also among 
the significantly enriched GO Cellular Components (Table 3.3). Additionally, the FUS 
interacting partners RTCB, CN166 and DDX1 are components of a tRNA splicing ligase 
complex that is not part of the spliceosome (Fig 3.8) (128). Although we did not identify 
FA98B/FAM98B, a fourth component of the tRNA splicing ligase complex as a FUS 
interacting partner, we did identify its closest human homolog, FA98A/FAM98A 
(Supplemental Table 3.1). The FUS-interacting RTCB/CN166/DDX1 complex was also 
reported to play a role in nucleo-cytoplasmic RNA shuttling (146), a function shared by 
FUS (101), suggesting potential functional co-operation. The familial ALS-related FUS 
mutations cause cytoplasmic mis-localization of FUS (2, 3, 12, 62, 63, 72). It is 
conceivable that the resulting lower nuclear FUS level leads to depletion of its nuclear 
complexes and loss of its nuclear functions. 
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 Mis-regulation of cytoplasmic processes by ALS mutant FUS 
 We identified 34 FUS interacting partners that are known components of either 
IMP1-dependent RNP granules, RNA transport granules, or both (Fig 3.8). IMP1, also 
called insulin-like growth factor 2 mRNA-binding protein 1 is an RNA binding protein that 
recruits target mRNAs to cytoplasmic protein-RNA complexes. IMP1 stabilizes the 
recruited mRNAs allowing their storage and transport and modulates the location at which 
the target mRNAs are translated (130, 147-149). IMP1 plays a direct role in the transport 
and translation of transcripts required for axonal regeneration (150). The IMP1-dependent 
RNP granules are distinct from RNA transport granules and stress granules (129), although 
they share components (Fig 3.7). The ALS-related FUS mutations cause the formation of 
FUS-positive cytoplasmic inclusions (12, 62, 63, 72) that sequestered the IMP1-dependent 
RNP granule and/or transport granule components DHX9, DDX3X, and CAPR1 (Fig. 
3.4, Fig. 3.5, Fig 3.7). The sequestration of these FUS interacting partners could lead to 
loss of their function in RNA transport and localized translation. Because of the extreme 
proportions of motor neurons, they rely on mRNA transport and localized translation more 
than other cell types. Accordingly, motor neurons could be especially sensitive to the 
sequestration of mRNA transport granule components. 
 We identified 21 reported stress granule (SG) components as FUS interacting 
partners (Fig. 3.7). We found that the cytoplasmic ALS mutant FUS inclusions were 
immunopositive for the SG components DDX3X and CAPR1 (Fig. 3.4, Fig. 3.5, Fig. 3.7). 
We previously reported that the mutant FUS inclusions were also immunopositive for 
another SG component, PABP1 (72). Stress granules are stress-induced ribonucleoprotein 
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complexes in eukaryotic cells that contain translationally silent pre-initiation complexes 
and a host of RNA-binding proteins (73, 151). Two of the FUS interacting proteins we 
identified were processing body or P-body components (Fig. 3.7). P-bodies are discrete 
cytoplasmic foci where mRNA degradation takes place (152). P-bodies functionally 
interact with stress granules (139). Among normal conditions, stress granules exist for up 
to a few hours. The normal dynamics of stress granules is critical for the survival of stressed 
neurons (73). The perturbation of stress granule dynamics might be a pathological process 
of central importance in ALS (138, 153, 154). Accordingly, triggering the formation of 
unusually stable stress granule-like structures by mutant FUS and the resulting perturbation 
of stress granule dynamics might cause a gained toxicity phenotype. 
 During the revision of this manuscript, a comparative interactomics study of varied 
ALS-associated proteins was published that identified a partially overlapping set of FUS 
interacting partners (155). 
3.4 Conclusions 
 In summary, our results demonstrate that the FUS interacting partners participate 
in multiple pathways, providing insights into the physiological functions of FUS as well as 
the potential mis-regulation of these pathways by ALS mutant FUS. Among the pathways, 
mRNA transport and stress granule dynamics are particularly important for the health of 
motor neurons. Mis-regulation of the dendritic and/or axonal mRNA transport and the 
generation of abnormally stable ectopic stress granule-like structures by ALS mutant FUS 
are likely contributors to ALS pathogenesis. 
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Table 3.1 Selected enriched GO Biological Processes among the identified FUS interacting 
partners.  
The corresponding p-values and the numbers of FUS interaction partners are shown 
without/with the inclusion of ribosomal FUS interaction partners in the search. 
Term p-Value Number of FUS interaction partners 
RNA processing 1.659e −32/3.050e −36 37/46 
RNA splicing 4.750e −27/2.960e −22 27/27 
mRNA processing 9.890e −27/1.499e −21 28/28 
mRNA metabolic process 1.149e −25/6.829e −73 30/67 
mRNA splicing, via spliceosome 1.149e −25/1.760e −21 23/23 
Gene expression 1.220e −18/3.089e −33 49/80 
Posttranscriptional regulation of 
gene expression 
6.050e −13/1.650e −13 17/20 
mRNA stabilization 2.940e −7/1.150e −6 6/6 
Regulation of translation 8.299e −7/3.019e −8 11/14 
RNA localization 1.980e −5/2.180e −4 8/8 
Transcription, DNA-templated 6.779e −5/4.710e −2 25/26 
mRNA 3′-end processing 3.570e −4/1.649e −3 5/5 
tRNA splicing, via 
endonucleolytic cleavage and 
ligation 
8.429e −4/1.699e −3 3/3 
ncRNA metabolic process 1.000e −3/3.459e −10 9/18 
Termination of RNA polymerase 
II transcription 
2.360e −3/8.259e −3 4/4 
Transcription from RNA 
polymerase II promoter 
5.130e −3/1.499e −1 11/11 
Chromosome organization 1.149e −2/2.939e −1 11/11 
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Table 3.2 Selected enriched GO Molecular Functions among the identified FUS interacting 
partners.  
The corresponding p-values and the numbers of FUS interaction partners are shown 
without/with the inclusion of ribosomal FUS interaction partners in the search. 
Term p-Value Number of FUS interaction partners 
RNA binding 5.000e −43/6.379e −74 53/87 
Single-stranded RNA 
binding 2.070e −10/9.300e −9 9/9 
ATP-dependent RNA 
helicase activity 2.220e −10/1.099e −8 9/9 
Double-stranded RNA 
binding 8.889e −6/1.289e −4 6/6 
mRNA 3′-UTR binding 4.350e −5/4.180e −4 5/5 
DNA binding 3.330e −4/2.750e −2 22/25 
RNA polymerase II core 
binding 1.690e −3/7.629e −3 3/3 
mRNA 5′-UTR binding 1.359e −2/5.000e −4 2/3 
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Table 3.3 Selected enriched GO Cellular Components among the identified FUS 
interacting partners. 
Term p-Value Number of FUS interaction partners 
Ribonucleoprotein complex 2.369e −68 66 
Ribosome 1.769e −46 38 
Spliceosomal complex 1.080e −20 20 
Ribonucleoprotein granule 3.200e −16 16 
Cytoplasmic stress granule 3.430e −10 8 
Extracellular exosome 1.430e −9 42 
tRNA-splicing ligase 
complex 1.919e −6 4 
SMN-Sm protein complex 5.140e −5 4 
Chromosome 2.449e −3 13 
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Figure  3.1  
The identification of FUS interaction partners. GST pull-downs were performed from 
cellular extracts of 293T cells transfected with the indicated GST expression constructs. 
RNase was included in the cellular lysates as indicated. The pull-down mixtures were 
subjected to SDS-PAGE on 4–15% gradient gel, followed by Sypro Ruby staining. Vec, 
vector. The molecular weights of marker bands are shown on the left (kDa). 
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Figure 3.2  
Verification of selected FUS interacting partners with endogenous FUS 
immunoprecipitation. Immunoprecipitations were performed from cellular extracts of SH-
SY5Y cells with a FUS-specific and a control (HA) antibody. The immunoprecipitates 
were subjected to SDS-PAGE followed by immunoblot with the indicated antibodies. IP, 
immunoprecipitation; Ext, extract; IB, immunoblot. The molecular weights of nearby 
marker bands are shown on the left (kDa). 
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Figure 3.3  
Verification of selected FUS interacting partners with GST-FUS pulldown. (A–B) GST 
pull-downs were performed from cellular extracts of 293T cells transfected with the 
indicated GST expression constructs. RNase was included in the cellular lysates as 
indicated. The pull-down mixtures were subjected to SDS-PAGE followed by immunoblot 
with the indicated antibodies. PD, pull-down; Ext, extract; Vec, vector; RG, R521G; PL, 
P525L; IB, immunoblot. The molecular weights of nearby marker bands are shown on the 
left (kDa). (C) Quantification of the RNA dependence of the FUS interactions shown in 
panel A. The band intensities from three independent experiments were quantified and 
normalized to the respective band with no RNase added. The error bars stand for standard  
deviation. Statistical significance was determined with Student's t-test. *: 0.01 < p < 0.05; 
**: 0.001 < p < 0.01; ***: p < 0.001.  
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Figure 3.4  
The co-localization of DHX9, DDX3X and Caprin-1 with ALS mutant FUS inclusions in 
SH-SY5Y cells. Confocal microscopic images of EGFP-tagged FUS (WT, R521G or 
P525L) fluorescence and DHX9 (A), DDX3X (B) and Caprin-1 (C) immunofluorescence 
in SH-SY5Y cells. The co-localization of mutant FUS and DHX9 in cytoplasmic inclusions 
is shown by arrows in (A). Scale bars, 10 μm. 
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Figure 3.5  
The co-localization of DHX9, DDX3X and Caprin-1 with ALS mutant FUS inclusions in 
primary cortical neurons. Confocal microscopic images of EGFP-tagged WT and P525L 
mutant FUS fluorescence and DHX9 (A), DDX3X (B) and Caprin-1 (C) 
immunofluorescence in cultured mouse primary cortical neurons. The boxed areas are 
magnified in the respective panels on the right. The co-localization of mutant FUS with the 
respective interaction partners in cytoplasmic inclusions is shown by arrows. Scale bars, 
50 μm. 
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Figure 3.6  
The Matrin-3, hnRNPA1 and ILF2 proteins do not localize to ALS mutant FUS inclusions 
in SH-SY5Y cells. Confocal microscopic images of EGFP-tagged FUS (WT, R521G or 
P525L) fluorescence and Matrin-3 (A), hnRNPA1 (B) and ILF2 (C) immunofluorescence 
in SH-SY5Y cells. Scale bars, 10 μm. 
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Figure 3.7  
FUS interacts with overlapping ribonucleoprotein complexes. Venn diagram of a subset of 
the identified FUS interacting partners. Venn diagram of a subset of the identified FUS 
interacting partners. The background diagram was obtained from Wikimedia 
Commons, https://commons.wikimedia.org/wiki/File:4-way-venn_vector.svg 
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CHAPTER 4. ALS MUTATIONS OF FUS SUPPRESS PROTEIN TRANSLATION AND DISRUPT 
THE REGULATION OF NONSENSE-MEDIATED DECAY 
Modified from the manuscript “ALS mutations of FUS suppress protein translation and 
disrupt the regulation of nonsense-mediated decay”, published in PNAS. 2018. Epub 
2018/11/21. doi: 10.1073/pnas.1810413115. PubMed PMID: 30455313. The introduction 
was simplified for fluidity. 
4.1 Introduction 
 FUS is a DNA- and RNA-binding protein that is primarily localized to the nucleus, 
where it forms dynamic ribonucleoprotein granules. In contrast, ALS-related mutant FUS 
accumulates in the cytoplasm and forms stable ribonucleoprotein granules, which can lead 
to inclusion bodies and potentially contribute to neurotoxicity (2, 3, 156). FUS mutations 
have also been shown to impact many RNA metabolic processes, including transcription 
(9, 13, 20, 22), splicing (37-39), mRNA transport (131), and stabilization (68), ultimately 
contributing to neuronal dysfunction. Recent studies demonstrated that mutations in FUS 
cause the liquid–liquid phase separation (LLPS) of FUS protein and the formation of self-
assembled hydrogels or liquid droplets in vitro (8, 157). It is noted that LLPS has also been 
reported for other RNA metabolic proteins involved in ALS, including TDP-43 (158), 
C9ORF72 dipeptide repeat (159), hnRNPA1 (158), and TIA1 (70). Thus, other cellular 
proteins are likely to be included in granules during LLPS in living cells, but the identities 
of such proteins remain to be determined.  
 This study started with testing the hypothesis that the identification of proteins 
associated with mutant FUS-dependent cytoplasmic granules is likely to provide critical 
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insights into the toxic mechanism of mutant FUS. We developed a protocol to capture the 
dynamic mutant FUS-positive granules (22, 156) by membrane filtration and identified 
protein components by proteomic approaches. The bioinformatics analysis of proteins 
identified in wild-type (WT) and mutant FUS granules revealed multiple RNA metabolism 
pathways, among which protein translation and mRNA surveillance appeared to be novel.  
 We thus hypothesize that mutant FUS plays a role in protein translation. Two 
previous studies reported that ALS-linked FUS mutations were recruited to 
ribonucleoprotein granules; thus, FUS was speculated to be involved in protein translation 
(66, 156). However, protein translation was not measured in either study. Using three 
independent assays, we found that mutant FUS indeed impaired protein translation and that 
the cytoplasmic inclusions of mutant FUS were positive for stalled ribosomal complexes.  
 Mutations in FUS have been demonstrated to cause aberrant splicing (160); 
however, the molecular mechanism by which cells handle defective mRNA has not been 
explored in ALS. Nonsense-mediated decay (NMD) is a major mRNA surveillance system 
that is known to degrade defective mRNA and ∼3– 20% of all mRNAs (161). NMD and 
protein translation are interrelated, as NMD utilizes the translocating ribosome as a 
proofreading mechanism for sensing defective mRNAs (162-164). We demonstrate that 
the phosphorylation level of a critical NMD regulator UPF1 (163), the NMD complex 
assembly, and theUPF1-mRNA binding all increased in the presence of mutant FUS, 
supporting that NMD is activated by mutant FUS. Additionally, two potent NMD-
activating regulators UPF1 and UPF3b (163, 165, 166) were up-regulated, while the 
negative NMD regulator UPF3a (167) was down-regulated in skin fibroblast cells derived 
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from a cohort of patients with ALS with FUS mutations compared with cells from control 
subjects, indicating disruption of the autoregulation of NMD. The hyperactivation of NMD 
was demonstrated using an NMD reporter assay in N2a cells and measuring endogenous 
mRNAs in the fibroblast cells of FUS ALS cases. Overall, the findings from this study thus 
provide an in-depth understanding of how RNA metabolism and protein translation are 
impacted by mutations in FUS and produce insights into the disease-causing mechanism 
of the mutant FUS subtype of ALS. 
4.2 Results 
 Proteins related to translation and mRNA surveillance are enriched in 
mutant FUS inclusions. 
 A more complete understanding of the protein composition that makes up the 
inclusions characteristic of mutant FUS-dependent ALS would provide a better 
understanding of the mechanism(s) driving the disease. To achieve this, we adapted a 
membrane filtration assay that was originally developed for detecting differentially soluble 
protein complexes (168). Utilizing previously described conditions in which 
radioimmunoprecipitation assay (RIPA) buffer was used to lyse cells (169), none of the 
WT, R495X, P525L, or R521G mutant FUS proteins were detected on the PVDF 
membrane (Fig. 4.1A). As a positive control and negative control, respectively, A4V 
mutant SOD1 was detected on the PVDF membrane filter, while WT SOD1 was not. The 
results suggest that, unlike A4V mutant SOD1-dependent cytoplasmic aggregates, mutant 
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FUS cytoplasmic inclusions are dynamic and disassembled under the experimental 
conditions.  
 A protocol using a hypotonic lysis buffer with a low detergent concentration was 
developed (Fig. 4.2A). Using these conditions, P525L and R495X mutant FUS was 
detected on the membrane filter along with A4V mutant SOD1, whereas less WT FUS was 
detected and no WT SOD1 was detected (Fig. 4.1B). Native gel electrophoresis (20) also 
confirmed that FUS protein remained as an oligomeric species under these conditions, 
whereas FUS protein prepared in the RIPA buffer migrated faster (Fig. 4.2B). We subjected 
the membrane “dots” to trypsin digestion followed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using a published protocol (169). A total of 291, 268, and 278 
proteins in FUS WT (Supplemental Table 4.1), R495X (Supplemental Table 4.2), and 
P525L (Supplemental Table 4.3), respectively, met the protein identification criteria 
described in SI Appendix and were considered significant identifications  
 Proteins identified in the granules were subjected to functional enrichment analysis 
using the integrative tool, Enrichr (90, 91). The Gene Ontology (GO): Molecular Function 
database (93) and the DISEASES database (94) were utilized for analyzing protein 
functions and disease relevance, respectively. The top 20 most significant molecular 
function annotations aggregated from the GO: Molecular Function database by Enrichr 
revealed a variety of RNA-binding functions associated with WT (Fig. 4.1C) and mutant 
FUS (Fig. 4.1D). It is noted that several properties, including translation factor activity, 
tRNA binding, and RNA cap binding, are related to protein translation and mRNA 
surveillance mechanisms. The top 10 most significant results from the disease-gene 
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association analysis for WT and mutant FUS (Fig. 4.3A) show a number of 
neurodegenerative diseases, including lateral sclerosis and Charcot–Marie–Tooth disease. 
Interestingly, the disease identified with a high significance was Diamond–Blackfan 
anemia, a severe ribosomopathy that results in defective protein synthesis(Fig. 4.3B) (170). 
This association suggests that proteins identified in FUS granules are likely to be involved 
in protein translation. We therefore focused on testing the function of FUS in protein 
synthesis and related mRNA surveillance pathways.  
 We next examined the subcellular localization of critical proteins involved in 
protein translation (eIF3, eIF4A1, eIF4G, and rpS6) and mRNA surveillance (eIF4A3) that 
were identified in the MS results. In primary cortical neurons transfected with EGFP-
tagged FUS, eIF4A3 (Fig. 4.1E), eIF3 (Fig. 4.1F), eIF4A1, eIF4G, and rpS6 (Fig. 4.4 A–
C, respectively) were all colocalized with cytoplasmic inclusions of mutant FUS. As a 
positive control, mutant FUS inclusions in primary neurons were positive for the stress 
granule marker G3BP1 (Fig. 4.4D) as previously reported (22). The immunoprecipitation 
(IP) results also demonstrated that eIF3, eIF4G, and eIF4A3 interacted more with the 
mutant than WT FUS (Fig. 4.1G), validating the proteomic and colocalization results. 
 Protein translation is impaired in the presence of mutant FUS 
Based on the above proteomic identifications, GO enrichment analysis, and colocalization 
of translation machinery to the mutant FUS inclusions, we set out to test whether protein 
translation is impaired by ALS mutants of FUS using three independent assays. Utilizing 
a translation reporter assay (84), we examined how mutant FUS changed cap-dependent 
protein translation. Co-transfection of R495X or P525L mutant FUS with the reporter 
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construct resulted in 50% and 70% reductions in the translation of the Renilla reporter 
gene, respectively (Fig. 2A). No detectable change was observed in cells transfected with 
empty vector (EV) or WT FUS. The control internal ribosomal entry site (IRES)- 
dependent translation of the luciferase gene was not changed (Fig. 4.5A). The second assay 
using an in vitro 35S-methionine (35S-Met) incorporation assay to measure translation of 
native mRNA showed that 35S-Met incorporation decreased by 25% and 35%, 
respectively, in the presence of mutant FUS compared with WT FUS or the EV control 
(Fig. 2B). Third, to examine endogenous protein translation, we used the surface sensing 
of translation (SUnSET) assay in which puromycin was used as a structural analog of 
aminoacyl tRNAs to prevent elongation after being incorporated into the nascent 
polypeptide chain (171). N2a cells were transfected with either EV, WT, or mutant FUS 
and treated with puromycin. Western blot analysis using an anti-puromycin antibody 
showed reduced translation in cells expressing mutant FUS (Fig. 4.5C and D). Finally, we 
carried out the SUnSET assay to examine protein translation in the skin fibroblast cells 
derived from patients with familial ALS who were carrying R521G or P525R (89) FUS 
mutations and from healthy controls with WT FUS (Fig. 4.5E and F). Protein translation 
decreased by ∼30% in fibroblast cells from FUS ALS cases. The above results consistently 
support that mutant FUS represses protein translation.  
 We next examined whether FUS inclusions contained puromycinlated proteins. 
Immunofluorescence using the same anti-puromycin antibody showed that puromycinlated 
proteins were colocalized with mutant FUS inclusions (Fig. 2G), suggesting that translation 
complexes are localized in mutant FUS inclusions. Moreover, to test whether mRNA was 
also localized to the inclusion, we performed RNA fluorescence in situ hybridization 
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(FISH) with two different RNA probes in N2a cells expressing WT or P525L mutant FUS. 
A generic Cy3 oligo d(T)21 probe was used to test mature polyadenylated mRNAs (Fig. 
4.5H). Mature mRNA was distributed throughout the cytoplasm in cells with EV or WT 
FUS. However, a significant accumulation of mRNA in the mutant FUS inclusions was 
observed, which is consistent with previous observations (172). FUS has been reported to 
regulate the splicing of its own transcript (39); thus, we tested a probe specific to FUS 
transcript (exon 4) and found that FUS mRNA was also localized to the mutant FUS 
inclusions (Fig. 4.4E). The results support that mutant FUS inclusions were colocalized 
with translation machinery and mature mRNAs. 
 We next examined whether translation initiation is impaired by mutant FUS. 
Binding of the initiation factor eIF4E to the 5′ cap of mRNA is the rate-limiting step in 
translation initiation where regulation often occurs (173). We performed a 7′-
methylguanosine (7′MG) pulldown as an in vitro cap-binding assay (174) in the presence 
of WT or mutant FUS. After 7′MG pulldown, key members of the preinitiation complex 
were observed (Fig. 4.5I). Similar levels of eIF4G, eIF4E, and eIF4A1 were pulled down 
regardless of the presence of WT or mutant FUS. Neither WT nor mutant FUS bound to 
the 5′ cap. As a negative control, eIF4A3 also did not bind to the 5′ cap. The results suggest 
that mutant FUS does not interfere with the binding of the initiation complex to the 5′ cap 
structure in the translation initiation stage. Thus, it is likely that translation is disrupted by 
mutant FUS after the initiation step, resulting in premature termination. 
 We hypothesized that prematurely terminated polypeptides resulting from defective 
translation in the presence of mutant FUS will be polyubiquitinated and targeted for 
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degradation. Therefore, we examined the level of K48-linked polyubiquitination in cells 
expressing WT or mutant FUS, since it is the major signal for targeting substrates for 
proteasomal degradation. Using an antiK48 polyubiquitination tandem ubiquitin-binding 
entity (175), we found that the K48 polyubiquitination level increased ∼1.5- to 1.8- fold in 
cells expressing mutant FUS compared with WT FUS and the EV control (Fig. 4.5J and 
K). In contrast, the level of K63-linked polyubiquitination, which is involved with other 
non-proteasomal processes, did not change with either WT or mutant FUS (Fig. 4.6). These 
results collectively support that ALS mutations in FUS cause defects in protein translation. 
 The NMD pathway is activated by mutant FUS 
Protein translation and mRNA surveillance pathways are interrelated(162, 164). It has been 
reported that the inhibition of protein translation elongation by cycloheximide (176) can 
up-regulate NMD factors and activate NMD (177). Thus, we set to examine whether 
mutations in FUS can impact the mRNA degradative pathway NMD. UPF1 (163, 166) and 
UPF3b (167) are two critical positive regulators of NMD, and UPF1 phosphorylation (p-
UPF1) is a critical step in NMD activation (163, 178). We evaluated the levels of UPF1, 
p-UPF1, and UPF3b in the skin fibroblast cells derived from six FUS ALS cases and five 
healthy controls (Fig. 4.7A). The antibody used for pUPF1 was an anti–phospho-Ser/Thr 
ATM/AMR substrate (p-S/T) previously reported (179). Quantitative results show that the 
protein level of UPF1 (Fig. 4.7B), p-UPF1 (Fig. 4.7C), and UPF3b (Fig. 4.7D) increased 
in patients with ALS compared with healthy controls by 25%, 70%, and 35%, respectively. 
Similarly, N2a cells expressing P525L or R495X mutant FUS had increased levels of UPF1 
and UPF3b (Fig. 4.8) and p-UPF1 (Fig. 4.9A). The results provide initial evidence that 
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NMD activation is elevated in the presence of mutant FUS in the cells of patients with ALS 
with mutations in FUS. 
 We next examined the subcellular localization of endogenous NMD factors in 
primary cortical neurons transfected with WT or mutant FUS. The colocalization of mutant 
FUS with UPF1 and pUPF1 was demonstrated using two different p-UPF1 antibodies: the 
p-S/T antibody used in the Western blot analysis (Fig. 4.7E) and a different antibody 
against phosphor-S1089 of UPF1 (180) (Fig. 4.7F). Two additional NMD factors, UPF3b 
(Fig. 4.7G) and XRN1 (Fig. 4.10A), were also localized in cytoplasmic inclusions of 
mutant FUS in primary neurons. SMG6 was not localized in mutant FUS inclusions serving 
as a control (Fig. 4.10B). Similar results were obtained from N2a cells expressing WT or 
mutant FUS. Cytoplasmic inclusions of FUS were positive for UPF1 and p-UPF1, UPF3b, 
and XRN1 (Fig. 4.9A– C). SMG6 and eRF3b showed little localization to mutant FUS 
inclusions in N2a cells (Fig. 4.9D and E). The colocalization of NMD factors in mutant 
FUS inclusions further suggests that mutant FUS may impact the NMD pathway. 
 Since the assembly of key NMD factors with UPF1 is a critical aspect of pathway 
activation (181, 182), we next examined the assembly of NMD factors in the presence of 
WT or mutant FUS. Endogenous UPF1 IP followed by Western blots for various NMD 
factors is shown in Fig. 4.11A. Quantitative analysis showed that the UPF1 interaction with 
p-UPF1, UPF3b, the endonuclease SMG6, and FUS increased ∼1.5- to 2.0-fold, with 
statistical significance in the presence of mutant FUS (Fig. 4.11B). In addition, the 
translation termination factor eRF3b increased in the presence of mutant FUS (Fig. 4.11B). 
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Enhanced assembly of NMD factors is additional evidence that NMD was activated by 
mutant FUS. 
 We also tested the interaction of core NMD factors with mRNAs. We treated cells 
with bromouridine to label mRNAs, immunoprecipitated the labeled RNA with anti-BrdU 
antibody (183), and assessed NMD proteins by Western blot (Fig. 4.11C). Quantitative 
analysis showed that higher levels of NMD components responsible for triggering NMD 
(eIF4A3 and UPF1) and mRNA degradation (SMG6 and XRN1) were bound to RNAs in 
the presence of mutant FUS (Fig. 4.11D). An RNA-binding protein, PABP1, was used as 
a loading control and showed similar loading in all samples. The above results consistently 
support that the NMD pathway was activated by mutant FUS. 
 NMD factors are dysregulated in fibroblasts in FUS ALS cases 
 We demonstrated earlier that two positive regulators of NMD (UPF1 and UPF3b) 
and UPF1 phosphorylation increased in the skin fibroblast cells derived from six FUS ALS 
cases compared with five healthy controls (Fig. 4.7A–D). The NMD pathway is tightly 
regulated by multiple mechanisms, including the molecular brake UPF3a (167). UPF3a 
competitively blocks the interaction of UPF3b with UPF2, thus delaying the activation of 
NMD. We examined protein levels of UPF3a in six FUS ALS cases (Fig. 4.12A) and found 
∼30% lower levels of UPF3a protein in the fibroblast cells from these patients (Fig. 4.12B). 
Similarly, UPF3a protein levels decreased in N2a cells overexpressing the R495X and 
P525L mutants (SI Fig. 4.13A and B). 
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 We further examined how the mRNA levels of UPF1, UPF3b, and UPF3a changed 
in the FUS ALS cases. The qPCR results show elevated levels of UPF1 (Fig. 4.12C) and 
UPF3b (Fig. 4.12D) and decreased levels of UPF3a (Fig. 5E) in the fibroblast cells of FUS 
ALS cases. Similar results were obtained for mRNA levels of these factors in N2a cells 
expressing WT or mutant FUS (Figs. 4.8C and D and Fig 4.13C). Consistent changes in 
both mRNA and protein levels of the pro-NMD factors (UPF1 and UPF3b) and the 
negative regulator (UPF3a) illustrate a pattern of NMD dysregulation in the mutant FUS-
linked familial patients with ALS, which will contribute to NMD hyperactivation. 
 UPF1-mediated autoregulation of NMD is impaired in FUS ALS cases 
 Core NMD factors, including UPF1 and UPF3b, are regulated through an intricate 
autoregulatory mechanism, by which their own mRNAs are targeted for NMD (177, 184). 
Given the dysregulation of NMD factors as shown above, we hypothesized that the ALS 
mutations in FUS disrupt the autoregulatory mechanism of NMD. To test this hypothesis, 
we first performed endogenous UPF1 IP followed by qPCR to examine whether the UPF1 
protein binds its own mRNA and UPF3b mRNA. Using normal goat serum as a control, 
UPF1 protein was specifically pulled down by a UPF1 antibody (Fig. 4.14A). Along with 
the UPF1 protein, UPF1 mRNA (Fig. 4.14B) and UPF3b mRNA (Fig. 4.14C) were also 
pulled down. We then overexpressed WT, P525L, or R495X mutant FUS in N2a cells and 
performed a similar RNA IP experiment (Fig. 4.14D–F). Quantitative analysis showed that, 
consistent with earlier results (Fig. 4.7A), higher levels of mutant FUS were pulled down 
with the UPF1 protein (Fig. 4.14D). More importantly, lower levels of UPF1 mRNA (Fig. 
4.14E) and UPF3b mRNA (Fig. 4.14F) were pulled down along with the UPF1 protein in 
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the presence of mutant FUS, suggesting that mutant FUS led to a lower turnover of UPF1 
and UPF3b mRNA by NMD. The dampened autoregulatory mechanism through UPF1 
binding supports the observation of increases in the mRNA and protein levels of UPF1 and 
UPF3b. 
 To further examine how decay is influenced by FUS mutations, we measured the 
UPF1, UPF3b, and UPF3a mRNA levels by qPCR after treating N2a cells expressing WT, 
P525L, or R495X mutant FUS with the transcriptional inhibitor actinomycin D. In cells 
expressing mutant FUS, the decay of UPF1 (Fig. 4.14G) and UPF3b (Fig. 4.14H) mRNA 
was significantly slower than in controls. In contrast, the mRNA decay of the NMD 
negative regulator UPF3a was significantly faster in cells expressing mutant FUS (Fig. 
4.14I). The results collectively support that the stability of NMD factor mRNA was 
dysregulated by mutant FUS in a UPF1-dependent manner (i.e., the NMD autoregulatory 
circuit is impaired). 
 Enhanced decay of NMD substrate in the presence of ALS mutant FUS 
 Based on the above findings on the dysregulation of NMD factors, we next tested 
whether the NMD activity is hyperactivated using four well-characterized NMD reporters 
[β-globin and GPX-1 with and without a premature stop codon (PTC)] (185), as well as a 
cohort of documented endogenous NMD substrates(186, 187). The levels of all four 
reporter transcripts (WT β-globin, WT GPX-1, PTC β-globin, and PTC GPX-1) were 
consistently lower in N2a cells expressing mutant FUS than in cells expressing WT FUS 
(Fig. 4.15). It is noted that the transcript levels in WT FUS-expressing cells were 
unchanged compared with the EV control, with the exception of PTC GPX1 (Fig. 4.15D). 
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The NMD reporter assays support higher NMD turnover of normal and PTC-containing 
mRNAs in the presence of mutant FUS. 
 To better characterize NMD activity, we measured the mRNA levels of three NMD 
substrates: ATF3, ATF4, and TBL2 (186, 187). Total mRNA levels of ATF3, ATF4, and 
TBL2 (Fig. 4.16A–C) decreased in N2a cells expressing R495X or P525L mutant FUS 
compared with cells expressing EV and WT FUS. As a control, mRNA levels of 
cyclophilin D did not change (Fig. 4.16D). We next measured the time course of mRNA 
levels after transcription inhibition by actinomycin D. The mRNA decay of ATF3, ATF4, 
and TBL2 (Fig. 4.16E–G) was significantly faster in cells expressing R495X or P525L 
mutant FUS compared with cells expressing WT FUS. As a control, the decay of 
cyclophilin D did not differ between cells expressing mutant and WT FUS (Fig. 4.16H). 
Furthermore, we examined whether higher levels of these mRNAs were associated with 
UPF1. UPF1 protein IP was performed followed by qPCR to measure the amount of UPF1-
bound mRNAs. While similar levels of UPF1 protein were immunoprecipitated (Fig. 
4.16I), higher levels of ATF3, ATF4, and TBL2 mRNAs were bound to UPF1 in the 
presence of mutant FUS (Fig. 4.16J–L). All three lines of evidence support the enhanced 
NMD decay of these endogenous substrates in cells expressing mutant FUS. 
 We next examined the mRNA levels of ATF3, ATF4, and TBL2 in fibroblast cells 
derived from patients with familial ALS. Indeed, the levels of all three mRNAs were lower 
in cells of patients with ALS than in healthy controls with WT FUS (Fig. 4.16M–O). The 
results suggest that the NMD activity is induced in clinically relevant samples. 
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4.3 Discussion 
 FUS (8, 157) and other proteins implicated in ALS (70, 158, 159, 188) have been 
reported to undergo LLPS and form liquid droplets, which facilitates the formation of 
membrane-less RNA-protein granules and inclusions (9, 22, 156). This study started with 
developing a method to isolate dynamic FUS-containing granules and identifying their 
protein compositions. Enrichment analysis of identified proteins implied that both WT and 
mutant FUS are involved in protein translation and mRNA surveillance (Fig. 4.1C and D 
and Fig. 4.3). Tight spatiotemporal regulation of protein synthesis in a motor neuron is 
critical for its function and survival (189), and reduced protein synthesis can be detrimental 
to normal neuronal function (190, 191). Moreover, mRNA surveillance is intimately 
integrated into protein translation (162). For instance, eIF4A3 is a core exon junction 
complex member that aids in initiating NMD (182). eIF3 is classically known as a critical 
initiation factor; however, it is also required for efficient translation termination in the 
event of NMD and promotes ribosomal recycling(192, 193). However, it is unknown how 
defects in mRNA surveillance are linked to suppression of protein synthesis by ALS 
mutation in FUS. The colocalization of eIF4A3 and eIF3 in mutant FUS inclusions (Fig. 
4.1E and F) led us to probe how protein translation and NMD are altered by mutant FUS 
and to discover the underlying mechanisms. 
 We used three independent assays to provide direct evidence that mutant FUS 
negatively impacted global protein production (Fig. 4.5A–D). Furthermore, the SUnSET 
assay also detected significant reduction of protein translation in fibroblast cells derived 
from patients with familial ALS with two different FUS mutations (Fig. 4.5E and F). In 
addition, mutant FUS inclusions were colocalized with mRNAs (Fig. 4.5H) and 
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puromycinylated peptides (Fig. 4.5G), suggesting that such inclusions are sites of defective 
protein synthesis with stalled translation complexes. Mutant FUS inclusions have been 
reported as stress granule-like with stress granule markers such as G3BP1 and TIA1, but 
they display altered dynamics compared with heathy cells with endogenous WT FUS (10, 
72, 194, 195). We suggest that the impairment of protein translation as shown in this study 
is a functional consequence of the sequestration of the translation machinery in mutant 
FUS inclusions. 
 The above results raised the question how mRNAs resulting from impaired 
translation would be handled. It was reported that suppression of translation using 
cycloheximide up-regulated proteins involved in the NMD pathway, particularly UPF1 and 
UPF3b (177). Our proteomic analysis also suggested that proteins involved in the mRNA 
surveillance pathway were enriched in mutant FUS inclusions. We observed increased pro-
NMD proteins UPF1 and UPF3b in fibroblast cells derived from a cohort of patients with 
familial ALS bearing two different FUS mutations, R521G and P525R (Fig. 4.7A–D), as 
well as in N2a cells expressing mutant FUS (Fig. 4.8). In addition, UPF1 phosphorylation 
(Fig. 4.7E and F), NMD complex assembly (Fig. 4.7A and B), and UPF1- mRNA binding 
(Fig. 4.7C and D) all increased in the presence of mutant FUS, suggesting an elevated level 
of NMD activity as we demonstrated with an NMD reporter assay (Fig. 4.15), in three 
endogenous NMD substrates in N2a cells expressing mutant FUS (Fig. 4.16A–H), and in 
fibroblast cells from patients with FUS ALS (Fig. 4.16M–O). We rationalized that higher 
levels of core NMD factors in mutant FUS inclusions would aid in the degradation of RNAs 
associated with prematurely terminated translation complexes, thus playing a protective 
role in FUS ALS. A yeast genetic screen identified that UPF1 rescued mutant FUS toxicity 
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in Saccharomyces cerevisiae (82), and follow-up studies showed a similar protective effect 
of UPF1 overexpression in primary neurons (83) and TDP-43 rat models (196). 
 Different from UPF1 and UPF3b, UPF3a functions as a molecular brake by 
competing with UPF3b for interaction with UPF2 and delaying activation of the pathway 
(167). To our surprise, we found that both protein and mRNA levels of UPF3a decreased 
in the same cells of patients with familial ALS with mutations in FUS (Fig. 4.12). Loss of 
the down-regulatory mechanism could result in aberrant activation of NMD. Moreover, 
NMD is regulated by an intricate autoregulatory circuit to prevent overt activation of NMD. 
Specifically, the mRNA levels of NMD factors UPF1 and UPF3b are degraded through the 
NMD pathway itself(177, 184). Our results from mRNA decay experiments demonstrate 
the stabilization of the pro-NMD factors UPF1 and UPF3b and an increased degradation 
of the negative regulator UPF3a (Fig. 4.15G–I), suggesting a disruption in the 
autoregulatory circuit. These results consistently support a model (Fig. 8) in which the 
NMD pathway is dysregulated and hyperactivated in the presence of mutant FUS. It was 
reported that UPF1 overexpression could increase the available pool of UPF1 to reactivate 
the autoregulatory feedback (184), thus enabling the degradation of UPF1 and UPF3b 
mRNAs and dampening the hyperactivation of NMD. This mechanism can provide an 
explanation of the reported protective effect of UPF1 overexpression in TDP-43 and FUS 
ALS models (82, 83, 196). 
 Dysregulation of NMD factors can, in turn, contribute to suppressing protein 
translation. For instance, besides its function of promoting NMD, UPF3b was reported to 
recruit termination factor eRFs to stalled ribosomes and to terminate protein translation 
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(197). Interestingly, mutations in UPF3b can result in intellectual disabilities, autism 
spectrum disorder, and schizophrenia. These disorders are likely the consequence of 
defective NMD in dendrites and neurons, which results in deficient neuronal maturation 
and dendritic branching (198, 199). 
 In mutant FUS ALS, translation suppression and subsequent NMD activation 
appear to constitute a vicious cycle, as illustrated in Fig. 8. Increased translation 
termination events, potentially due to increased binding of mutant FUS to mRNAs, activate 
NMD at higher levels. Furthermore, the autoregulation of NMD is disrupted as the pro-
NMD factors UPF1 and UPF3b increase and the molecular brake UPF3a decreases, 
contributing to the hyperactivation of NMD and increased degradation of natural NMD 
targets, such as ATF3, ATF4, and TBL2. This hyperactivity resulting from defects in 
translation termination may contribute to toxicity in motor neurons (Fig. 4.17). It is noted 
that critical steps in this model, including suppressed protein translation (Fig. 4.5E and F); 
increased levels of UPF1, p-UPF1, and UPF3b protein (Fig. 4.7A–D) and mRNA (Fig. 
4.12C and D); decreased levels of UPF3a protein (Fig. 4.12A and B) and mRNA (Fig. 
4.12E); and increased NMD degradation of ATF3, ATF4, and TBL2 mRNAs (Fig. 4.16 
M–O), were consistently supported by results from fibroblast cells derived from patients 
with familial ALS carrying two different FUS mutations. 
 Although this study only demonstrated that mutant FUS suppressed global protein 
translation, it is conceivable that local translation in dendrites and axon terminals may also 
be impaired by mutant FUS. FUS has been demonstrated to be part of RNA transport 
granules and to be recruited to activated synapses (33, 66, 200). In cells bearing FUS 
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mutations, however, there are defects in synaptic morphology and function (33, 191, 200-
202). Decreases in proteins required for synaptic maintenance and function may contribute 
to an ALS phenotype. Additionally, overactivation of NMD may produce deleterious 
effects in stress response pathways, including how cells respond to misfolded proteins, 
hypoxia, and DNA damage (161, 177). NMD also functions in fine-tuning the immune 
response by degrading mRNAs of proinflammatory factors (203). As neuroinflammation 
plays a role in ALS in a non–cell autonomous fashion (204, 205), it is conceivable that 
dysregulation of NMD in astrocytes and microglia may also impact the immune response 
and contribute to the ALS phenotypes. 
 In summary, the mechanistic insights gained from this study begin to describe the 
role of FUS in protein translation and a critical mRNA quality control pathway, both of 
which are required for neuronal maintenance and function. Sequestration of UPF1 in 
mutant FUS inclusions, decrease in protein synthesis, NMD hyperactivation, or a 
combination of these events likely plays a role in neurodegeneration in ALS. It is noted 
that suppressed protein translation (Fig. 4.5E and F), NMD activation (Fig. 4.7A–D), 
disrupted NMD autoregulation (Fig. 4.12), and hyperactivity of NMD (Fig. 4.16M– O) 
were consistently demonstrated in the fibroblast cells of patients with ALS with mutations 
in FUS.  
 These mechanistic understandings support the notion that regulation of NMD and 
protein translation can serve as potential therapeutic targets for future development of new 
ALS treatment. The results also have a broader impact, since other RNA-binding proteins 
all undergo LLPS and form cytoplasmic granules, including TDP-43, C9ORF72 dipeptide 
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repeat, hnRNPA1, and TIA1 (70, 158, 159, 188). Future studies will investigate whether 
these proteins, which are implicated in ALS, frontotemporal dementia, and related 
disorders, also influence the mRNA quality control pathway and impair protein translation. 
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Figure 4.1  
Proteomic identification, enrichment analysis, and validation of proteins in WT or mutant 
FUS inclusions isolated by membrane filtration. Membrane filtration, followed by dot 
blotting of granules isolated using the RIPA buffer (A) or the low-detergent hypotonic lysis 
buffer (B), was performed. The molecular function of proteins identified in WT (C) or 
mutant (D) FUS inclusions was analyzed using Enrichr software with the GO: Molecular 
Functions database. The top 20 most significant (P < 0.05) molecular functions are 
represented. Immunofluorescent staining of eIF4A3 (E) and eIF3 (F) in mouse primary  
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Figure 4.1 Continued 
cortical neurons was performed. Arrows indicate inclusions where proteins of interest are 
colocalized. (Scale bars: regular view, 20 μm; zoomed-in views, 5 μm.) (G) FUS IP, 
followed by Western blot for translation initiation factors (eIF4AIII, eIF3, and eIF4G) that 
were uniquely identified in mutant FUS inclusions. 
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Figure 4.2  
Native gel electrophoresis of FUS protein in a low detergent hypotonic lysis buffer. 
Workflow of the membrane filtration protocol to isolate FUS inclusions using a low 
detergent hypotonic lysis buffer. (B). Native gel electrophoresis to assess the migration of 
WT FUS and mutant (R495X and P525L) FUS in the low detergent hypotonic lysis buffer. 
WT and A4V mutant SOD1 were included as controls. 
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Figure 4.3  
Diseases associated with proteins identified in WT (A) or mutant (B) FUS inclusions as 
analyzed using Enrichr software. The top 10 most significant (p <0.05) diseases are 
presented. Blue bars represent neurological or neurodegenerative diseases, while the red 
bar represent a ribosomopathy 
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Figure 4.4  
Colocalization of mutant FUS with selected proteins in mouse primary neurons (A-D) and 
RNA (E) in N2a cells. Immunofluorescent staining of eIF4A1 (a), eIF4G (b), RPS6 (c), 
and G3BP1 (d) in primary neurons transfected with EGFP-tagged WT or mutant FUS. (e). 
RNA FISH using an anti-FUS exon 4 RNA probe. Arrows indicate inclusions where 
proteins of interest are colocalized. Scale bars equal to 20 µm in regular views and 5 µm 
in zoomed views. 
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Figure 4.5  
Protein translation is impaired in the presence of mutant FUS. (A) Cap-dependent 
translation assay using the luciferase reporter in N2a cells expressing EV, WT, or mutant 
FUS. Blue and red bars represent the luminescence of the Renilla cap dependent reporter 
and the Firefly luciferase transfection control, respectively. (B) In vitro 35S-Met 
incorporation assay using rabbit reticulocyte lysate mixed with N2a cell lysate containing 
EV, WT, or mutant FUS. After 1 h of incubation, proteins were precipitated, and 
radioactivity was measured using a scintillation counter. Counts were normalized to the  
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Figure 4.5 Continued 
EV. (C and D) SUnSET assay measuring puromycin incorporated into proteins during 
translation in N2a cells expressing EV, WT, or mutant FUS. Western blots of  
puromycinylated proteins, FUS, and actin loading control are shown in C. Quantification 
in D was performed using the intensity of puromycinylated proteins in each lane to 
normalize against Actin and EV. (E and F) SUnSET assay measuring 
puromycinincorporated into proteins during translation in fibroblast cells of patients with 
FUS ALS. Western blots of puromycinylated proteins and a GAPDH loading control are 
shown in E, and quantification results are shown in F. (G) Immunofluorescent staining of 
puromycinylated proteins in N2a cells expressing EV or EGFP-tagged WT or mutant FUS. 
Cells were incubated with puromycin for 30 min, fixed using paraformaldehyde (PFA), 
and stained with the antipuromycin antibody. (Scale bars: 20 μm.) (H) RNA FISH using a 
Cy3-tagged 21-mer oligo d(T) probe in N2a cells expressing WT or mutant FUS. (Scale 
bars: 20 μm.) (I) 7′MG pulldown to assess the cap binding and protein translation initiation 
in N2a cell lysate containing WT or mutant FUS. Various initiation complex members 
(eIF4E, eIF4G, and eIF4AI), FUS, and a negative control (eIF4AIII) were blotted. (J) K48 
polyubiquitination in N2a cells expressing EV, WT, or mutant FUS with FUS expression 
and actin loading control. (K) Quantification of J using the K48 polyubiquitination 
intensity in each lane to normalize against actin and EV. Error bars in the figure represent 
SDs for three biological replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not 
significant. ANOVA with a post hoc Tukey honest significant difference test was used to 
determine P values for multiple pairwise comparisons in A, B, D, and K. A Student’s t test 
was used to determine P values for simple pairwise comparison in F.   
 
 
92 
 
 
Figure 4.6  
K63-linked polyubiquitination did not change in the presence of mutant FUS. (A). Western 
blot for K63 polyubiqitinated proteins in N2a cells transfected with WT or mutant FUS. 
(B). Quantification of (a) using intensities in each lane normalized against Actin and 
compared to EV. Error bars represent the standard deviation for three biological replicates. 
No statistical significance was found among samples using a Students T-test.   
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Figure 4.7  
Up-regulation of pro-NMD factors in cells of patients with familial ALS and in primary 
neurons expressing mutant FUS. (A–D) Levels of pro-NMD factors in patients with ALS  
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Figure 4.7 Continued 
Fig. 4.17 Continued carrying the R521G or P525R mutation and in control subjects with 
WT FUS. Western blots of UPF1, p-UPF1, UPF3b, and actin control were performed (A), 
and quantification of UPF1 (B), p-UPF1 (C), and UPF3b (D) was normalized against actin 
and obtained from three replicates. Error bars represent the SD between individuals. 
Quantifications were compared with healthy controls using a Student’s t test. *P ≤ 0.05; 
**P ≤ 0.005. (E–G) Immunofluorescent staining of UPF1, p-UPF1, and UPF3b in mouse 
primary neurons transfected with EV, EGFP-tagged WT, or mutant FUS at day 4 of in vitro 
culture. (E) Immunofluorescent staining of UPF1 and p-UPF1 using an anti–p-S/T 
ATM/AMR substrate antibody. (F) Immunofluorescent staining of p-UPF1 using an 
antibody against phosphor-S1089 in UPF1. (G) Immunofluorescent staining of UPF3b. 
Arrows indicate inclusions where proteins of interest are colocalized. (Scale bars: regular 
views, 20 μm; zoomed-in views, 5 μm.). 
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Figure 4.8  
Increased protein (A-B) and mRNA (C-D) levels of UPF1 and UPF3b in N2a cells 
expressing mutant FUS. (A). N2a cells were transfected with WT or mutant FUS and the 
protein levels of UPF1 and UPF3b were assessed by SDS-PAGE followed by Western blot. 
(B). Quantification of UPF1 and UPF3b Western blot as normalized to Actin and compared 
to the EV. (C-D) qPCR quantification of the mRNA levels of UPF1 (c) and UPF3b (d) in  
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Figure 4.8 continued 
N2a cells transfected with WT or mutant FUS. Quantification was performed using the 
∆∆cT method and presented as fold changes as compared to EV. Error bars represent 
standard deviations for three biological replicates. P values are determined using a Students 
T-test. * p≤0.05, ** p≤0.005, and *** p≤0.001. 
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Figure 4.9  
Immunostaining of NMD factors and FUS in N2a cells. N2a cells were transfected with 
empty vector (EV), or EGFP-tagged WT or mutant FUS, and stained for endogenous UPF1 
(A), phospho-UPF1 (A), UPF3b (B), XRN1 (C), SMG6 (D), and eRF3b (E), respectively. 
All scale bars equal to 20 µm. 
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Figure 4.10  
Immunostaining of XRN1 (A), SMG1 (B) and SMG6 (C) in mouse primary neurons. 
Mouse primary cortical neurons were transfected with empty vector (EV), or EGFP-tagged 
WT or mutant FUS and stained for the indicated proteins. Arrows indicate inclusions where 
proteins of interest are colocalized. Scale bars equal to 20 µm in regular views and 5 µm 
in zoomed views. 
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Figure 4.11 
 Interaction of NMD factors with UPF1 and RNAs increased in the presence of mutant 
FUS. (A and B) NMD factors coprecipitated with endogenous UPF1 from N2a cells 
expressing EV, WT, or mutant FUS. Immunoblots of UPF1, p-UPF1, eRF3b, UPF3b, 
SMG6, and 3Å~ FLAG-FUS are shown in A, and quantitative results are shown in B. 
Protein intensities were normalized to corresponding UPF1 bands and compared with EV. 
(C and D) NMD factors coprecipitated with BrdU-containing RNAs. N2a cells expressing  
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Figure 4.11 Continued 
EV, WT, or mutant FUS were incubated with 1 μM BrdU, and RNAs were UV cross-linked 
to proteins. BrdU IP was performed using an anti-BrdU antibody, followed by Western 
blots for UPF1, eIF4A3, XRN1, SMG6, FUS, PABP1, and actin. BrU, bromouridine. 
Quantification of proteins in C is shown in D. Proteins were normalized to the loading 
control, PABP1, and compared with EV. The purple, green, blue, and red bars represent 
EV, WT FUS, R495X FUS, and P525L FUS, respectively. Error bars represent SDs for 
three biological replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. Quantifications were 
compared with EV using a Student’s t test. 
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Figure 4.12 
Down-regulation of the NMD negative regulator UPF3a in cells of patients with familial 
ALS. (A and B) Protein levels of the NMD negative regulator UPF3a in six patients with 
ALS and five control subjects, as shown in Fig. 3 A and B. Western blots of UPF3a and an 
actin control (A) and quantification of UPF3a normalized against actin (B) are shown. (C–
E) Quantification of mRNA levels of dysregulated NMD factors. qPCR of UPF1 (C), 
UPF3b (D), and UPF3a (E) was performed using the cycle threshold method and is 
presented as the fold change in patients with ALS versus controls. Actin was used to 
normalize cycle threshold values. Error bars represent the SD between individuals. *P ≤ 
0.05; **P ≤ 0.005. Quantifications were compared with healthy controls using a Student’s 
t test.   
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Figure 4.13  
Decreased protein (A-B) and mRNA (C) levels of UPF3a in N2a cells expressing mutant 
FUS.N2a cells were transfected with empty vector (EV), or WT or mutant FUS and the 
protein levels of UPF3a were assessed by SDS-PAGE followed by Western blot. (B).  
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Fig. 4.13 Continued 
Quantification of UPF3a Western blot as normalized to Actin and compared to the EV. 
(C). qPCR quantification of the mRNA levels of UPF3a in N2a cells transfected with WT 
or mutant FUS. Quantification was performed using the ∆∆cT method and presented as 
fold changes as compared to EV. Error bars represent standard deviations for three 
biological replicates. ** p≤0.005, and *** p≤0.001. Students T-test was used to determine 
p values. 
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Figure 4.14  
Disruption in the NMD autoregulation loop. Endogenous UPF1 IP from N2a cells was performed, followed by Western blot (A) 
and qPCR measurement of UPF1 (B) and UPF3b (C) mRNAs. N2a cell lysate was subjected to IP using normal goat serum 
(NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot (A) and qPCR quantification (B and C) 
comparing RNA coprecipitated with UPF1 protein versus NGS control. UPF1 IP from N2a cells expressing EV, WT, or mutant 
FUS was performed, followed by Western blot (D) and qPCR measurement of UPF1 (E) and UPF3b (F) mRNAs. UPF1, FUS, 
and GAPDH were assessed by Western blot, as shown in D. qPCR quantification was normalized to UPF1 protein precipitate
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Figure 4.14 Continued 
and presented as fold change compared with EV. Turnover rates of UPF1 (G), UPF3b (H), 
and UPF3a (I) mRNAs in N2a cells expressing EV, WT, or mutant FUS are shown. 
Actinomycin D or DMSO control was added 2 or 4 h before harvesting for RNA isolation. 
Individual mRNAs of interest were quantified by qPCR, normalized against RPL13a, and 
presented as fold change versus DMSO treatment over time. Error bars represent the SD 
from three replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA 
with a post hoc Tukey honest significant difference test was used in E–I, and a Student’s t 
test was used in B and C.  
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Figure 4.15  
The NMD activity in the presence of WT or mutant FUS using an NMD reporter assay. 
NMD activity assay was carried out using the WT β -globin (A), WT GPX-1 (B), β-globin 
PTC (C), or GPX-1 PTC (D) reporter. N2a cells were cotransfected with empty vector 
(EV), or WT or mutant FUS and an NMD reporter as indicated. The levels of the indicated 
reporter transcript were quantified by qPCR using the ∆∆cT method. The fold changes as 
compared to EV are presented. ANOVA with post hoc Tukey HSD test was used to 
determine p-values for multiple pair-wise comparisons.   
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Figure 4.16  
Enhanced NMD activity in the presence of mutant FUS.The mRNA levels of ATF3 (A), 
ATF4 (B), TBL2 (C), and cyclophilin D (D) in N2a cells transfected with EV, WT, or  
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Figure 4.16 Continued 
mutant FUS were determined. The levels of the indicated mRNA were quantified by qPCR 
using the cycle threshold (ΔΔCT) method, and the fold changes compared with WT are 
presented. Turnover rate of ATF3 (E), ATF4 (F), TBL2 (G), and cyclophilin D (H) mRNAs 
in N2a cells expressing EV, WT, or mutant FUS after treatment with actinomycin or 
DMSO control. Individual mRNAs of interest were quantified by qPCR, normalized 
against RPL13a, and presented as fold change versus DMSO treatment over time. Error 
bars represent the SD from three replicates. (I–L) Amount of ATF3, ATF4, and TBL2 
mRNA bound to the UPF1 protein. N2a cells were cotransfected with EV, WT, or mutant 
FUS and an NMD reporter as indicated. After UPF IP, Western blot (I) demonstrates levels 
of UPF1 in lysate and IP samples. The levels of ATF3 (J), ATF4 (K), and TBL2 (L) mRNA 
in the UPF1 IP samples were quantified by qPCR using the ΔCT method. The fold changes 
normalized to WT are presented from three replicates. The mRNA levels of ATF3 (M), 
ATF4 (N), and TBL2 (O) in fibroblast cells derived from patients with familial ALS 
carrying FUS mutations and healthy WT controls are shown. *P ≤ 0.05; **P ≤ 0.005; ***P 
≤ 0.001. N.S., not significant. ANOVA with a post hoc Tukey honest significant difference 
test was used to determine P values in A–L. A Student’s t test was used to determine P 
values in M–O. 
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Figure 4.17  
Model illustrating how mutant FUS impairs NMD regulation and suppresses protein 
translation. (A) Normal translation and basal NMD under physiological conditions with 
WT FUS. (B) Mutant FUS has greater binding ability to mRNAs and associated proteins, 
including UPF1, leading to ribosomal stalling, translation termination, and subsequent 
activation of NMD. Up-regulation of pro-NMD factors (UPF1 and UPF3b) and down- 
regulation of the molecular brake (UPF3a) cause the loss of autoregulation and 
hyperactivity of NMD. pA, poly(A) tail.  
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CHAPTER 5. THE ROLE OF ENDOGENOUS FUS IN NONSENSE MEDIATED DECAY 
5.1 Introduction  
 FUS is a member of the FET family of DNA- and RNA-binding proteins that are 
primarily localized to the nucleus. FUS forms dynamic ribonucleoprotein granules in the 
nucleus to maintain efficacious transcription and splicing (2, 13, 20, 21, 29, 37-39, 45, 52, 
53, 113, 160, 169, 206-209). In contrast, ALS-related mutations in FUS cause its 
accumulation in the cytoplasm and the formation of inclusion bodies. These granules can 
lead to the formation of inclusion bodies and potentially contribute to neurotoxicity (2, 3, 
156). However, whether the formation of these inclusions and neurotoxicity are due to loss 
of function or a toxic gain of function when FUS is mutated remains to be understood. To 
clarify the cellular consequences of FUS mutations, utilization of FUS knockout (KO) 
systems are critically important. FUS KO cells and mice provide a platform to observe the 
biochemical and physiological outcomes of the loss of FUS in a wide variety of cell types 
across the central nervous system.  
 Understanding the repercussions of FUS (KO) in a neuronal system are essential 
for determining FUS’ major role causing ALS. While FUS KO result in embryonic lethality 
(210-212), conditional KO after birth does not cause motor neuron dysfunction, as 
homozygous mice did not exhibit an ALS phenotype (210). FUS KO has been 
demonstrated to have detrimental impacts on the behavior and brain structure of mice 
(210). Affected mice displayed hyper-activity and anxiety-like behavior but did not display 
defective Gem morphology previously observed (206, 207, 213). Demonstration of an FTD 
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phenotype without a disruption in motor function is illustrative of important transcriptome 
changes that may be brain-region and cell-type specific (210).  
 KO of FUS has been used as a cell-based tool to better understand if ALS-related 
mutations in FUS contribute to a gain or loss of function of the protein. FUS’ role in 
splicing has been well defined using KO cells and animals. Splicing changes that occur 
when FUS is knocked out has been well described and compared in detail to changes that 
occur in FUS mutants (206). Overall, loss of FUS results in gross changes to the 
transcriptome due to loss of Gems, and therefore reduced levels of snRNPs. Reduced 
snRNP levels are likely to contribute to changes in gene expression. In this regard, loss of 
FUS greatly mimics FUS mutations, as the presence of FUS in the nucleus is required for 
normal splicing. RNA seq using FUS knockdown in human fibroblasts demonstrates 
reduction of splicing factors, as well as other important genes for neuronal function (40). 
These data imply that mutations in FUS result in a nuclear loss of function. 
 Recently, studies to examine FUS’ cytoplasmic role have begun to demonstrate its 
importance in translation and maintenance of RNA stability (67, 214). These studies bring 
additional complexity as to whether mutations in FUS are a loss of function or toxic gain 
of function. For example, consistent changes in gene expression lead to changes in 
particular protein levels. WT FUS and ALS mutants have been demonstrated to interact 
with translation factors (214) and FUS inclusions have been demonstrated to hinder 
translation in both cellular and animal models (67, 214). Mechanistically, how FUS 
regulates and interacts with proteins within these processes has remained to be better 
defined, but deeper biochemical studies may yield clues as to the nature of their interaction 
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and how they contribute to ALS. Additionally, studies exploring mutant FUS’ role in 
activation of mRNA degradative pathways raised the question as to whether WT FUS plays 
a role in maintaining the balance of nonsense mediated decay (NMD). NMD serves as a 
post-initiation regulatory step for protein translation and is initiated due to errors and 
regulatory elements within mRNA, as well as when protein translation is stalled  (164).  
 In our exploration of how mutations in FUS initiate NMD, we observed a novel 
interaction between WT FUS and UPF1. However, overexpression of WT FUS does not 
perturb the pathway, it is possible that endogenous FUS may be important for regulation 
of UPF1 activity and NMD. Based on publicly available CLIP data (215), FUS has been 
reported to interact with UPF1 mRNA, as well as the mRNA of UPF2, UPF3a, UPF3b, 
SMG1, SMG5, SMG6, SMG7, and SMG8. It is worth noting that these RNA species are 
auto-regulated through the NMD pathway. Therefore, we hypothesized that one of FUS’ 
endogenous functions is to aid in autoregulation of NMD. Using N2A stable FUS knockout 
cells (termed NCF in this chapter), we probed for basic changes in NMD regulation and 
function. Specifically, we examined the steady state levels of NMD factors and substrates, 
UPF1 interaction with effector proteins, and the stability of NMD factors. 
5.2 Results 
 FUS Binds NMD Factor mRNA 
 The availability of large data sets through CLIPdb has allowed us to examine 
potential mRNA targets that FUS protein may bind (215). We initially probed the database 
for FUS’ interaction with NMD factor mRNA that is also subject to autoregulation through 
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the pathway. We found that FUS has been reported to bind to UPF1, UPF2, UPF3a, UPF3b, 
SMG1, SMG5, SMG6, SMG7, and SMG8 mRNA. The stabilities mRNA species are 
autoregulated through the NMD pathway (184). Our first experimental step in 
understanding endogenous FUS’ role in NMD was to confirm the CLIPdb FUS/mRNA 
interaction results (215). We selected five critical NMD factor’s mRNA to examine: UPF1, 
UPF2, UPF3b, SMG6, and SMG7. Using a FUS RNA IP, we immunoprecipitated FUS 
protein and using rt-qPCR, we measured the mRNA levels of the selected RNA species 
bound to FUS. We demonstrated that the results found in the CLIP data base were 
consistent with our qPCR data, with the exception of UPF1 mRNA (data not shown), which 
we found did not interact with FUS. This may be due to cell type differences, however. 
FUS bound UPF3b (Fig. 5.1A), UPF2 (Fig. 5.1B), SMG6 (Fig. 5.1C), and SMG7 mRNA 
(Fig. 5.1D). These results indicate that FUS may regulate NMD factors levels through 
mRNA binding, with the exception of UPF1. List of additional primers used are attached 
in Supplemental table A. 
 FUS Binds NMD Substrate mRNA 
 In addition to using the CLIP database to identify NMD factor mRNA that binds 
FUS, we also probed for NMD substrates that may interact with the FUS protein. We 
searched CLIPdb (215) and found that FUS protein was previously published to bind 
ATF3, ATF4, and TBL2 mRNA. We next wanted to examine FUS’ binding with natural 
NMD substrate mRNA: ATF3, ATF4, and TBL2 experimentally. We previously found that 
ALS-related mutations in FUS facilitated NMD decay these substrates (214), however the 
interactions between FUS and these mRNA substrates was not examined. Using a FUS 
 
 
114
RNA immunoprecipitation, we pulled-down mRNA bound to FUS protein and used rt-
qPCR to measure the levels of mRNA binding. We discovered that FUS binds all three of 
these mRNA species. While the levels of binding are not particularly high in ATF3 (Fig. 
Fig. 5.2A) and TBL2 (Fig. 5.2C), they are still significantly higher than the FUS KO (NCF) 
background control. FUS bound ATF4 mRNA as well (Fig. 5.3B). It should be noted that 
the qPCR data presented were generated from the same set as the previous set of FUS RNA 
IPs (Fig. 5.1) and therefore have the same western blot demonstrating effective 
immunoprecipitation (Fig 5.2D). We conclude that endogenous FUS binds NMD substrate 
mRNA, however, a more comprehensive list of substrates may be identified through RNA-
Seq. Overall, we can conclude that FUS does bind these NMD substrates and therefore, 
may play a role in maintaining their regulation and gene expression.  
 FUS Knockout Downregulates Pro-NMD Factor Proteins 
 Following up on FUS’ binding to NMD factor mRNA, we hypothesized that FUS 
would have an influence on the steady state levels of the selected proteins. Thus, we 
examined whether the steady state protein levels are changed when FUS is knocked out 
and whether they are rescued when FUS is re-expressed. Western blots demonstrated 
modest reductions of SMG1, SMG5, SMG6, SMG7 (Fig. 5.3A), UPF1, UPF3a, and UPF3b 
(Fig. 5.3B) protein levels. Protein levels of eIF4A3, RNPS1, and actin (Fig. 5.3C) did not 
change at the protein level. Interestingly, XRN1 proteins was significantly reduced in the 
FUS KO cells by approximately 10% (Fig. 5.3C). Western blots were quantified and 
represented Fig. 5.3D. We observed a rescue of protein levels when FUS was re-expressed, 
strongly indicating that knockout of FUS is directly responsible for reductions in protein 
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levels. These data imply that FUS’ interaction with NMD factor mRNA (Fig. 5.1) may play 
a role in regulating the protein levels of NMD factors through RNA binding.  
 FUS KO Reduces NMD Complex Assembly 
 Decreased protein levels of NMD factors led us to question if the NMD pathway 
activity is reduced when FUS is knocked out. A readout for the pathway activity is to 
examine NMD complex formation. Thus, we performed a UPF1 IP and western blotted for 
core NMD factors. We observed reduced interaction between UPF1 and UPF3b, SMG6, 
SMG7, and UPF2 (Fig. 5.4A, B) indicating that NMD complex levels in FUS KO cells are 
reduced as compared to WT N2A cells but rescued by re-expressing WT FUS. These data 
suggest two possible reasons for a reduction in complex assembly: 1) FUS protein is 
required for complex formation and/or 2) FUS KO’s reduction in NMD factor protein 
levels directly translates into reduced complex formation. It appears as though NMD 
activity may be suppressed due to reduced levels of effector proteins and their effector 
complexes. 
 FUS Knockout Downregulates Pro-NMD Factor mRNA 
 To determine if FUS KO’s changes in NMD factor protein levels are due to 
decreased mRNA levels, we examined the steady-state levels of NMD factor mRNA. We 
performed rt-qPCR to examine mRNA levels of UPF1, UPF2, UPF3b, and SMG1 (Fig. 
5.5A-D). We observed depressed mRNA levels of NMD factors, with modest to complete 
rescue by re-expression of WT FUS. Levels of XRN1, eIF4A3, and CyclophilinD mRNA 
(Fig. 5.5E-G) did not change. These data suggest that FUS binds NMD factor mRNA and 
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maintains mRNA levels, and that KO results in reduced mRNA and protein levels. We 
conclude that FUS is required for maintenance of NMD factor mRNA levels.  
 Stability of NMD Factors is Unchanged when FUS is Knocked Out 
 As we observed reductions in steady state levels of NMD factor mRNA and 
proteins, we hypothesized that these mRNAs would have reduced stability and higher 
turnover in the absence of FUS. We examined the stability of UPF1, UPF3b, SMG6, and 
SMG7. Using an actinomycin D time course assay paired with rt-qPCR, we found that the 
stability of UPF1, UPF3b, SMG6, and SMG7 are unchanged (Fig. 5.6A-D), and therefore 
the decay of these NMD factors was not impacted by the loss of FUS. These results were 
unexpected but yielded very interesting information on how FUS regulates NMD. These 
data, in combination with the reduced steady state mRNA levels (Fig 5.5) suggest that FUS 
regulates NMD factor expression at the transcriptional level. Furthermore, this stability 
data and steady state data demonstrate that the nuclear function of FUS (e.g. transcription 
regulation) may impact its cytoplasmic functions and pathways (e.g. regulation of NMD or 
translation).  
 FUS KO Reduces UPF1 Binding to NMD Factor mRNA 
 In previous studies we identified WT FUS as a novel binding partner for UPF1 
(214). UPF1 is a dynamic protein that acts as an RNA helicase with ATPase activity that 
regulates its binding affinity to RNA. Additionally, it serves as a binding platform for other 
NMD effector proteins (162, 163). Better understanding of the dynamics between FUS and 
UPF1 may help us understand how FUS participates in NMD. UPF1’s RNA binding ability 
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is critical to its function in triggering NMD (185). To understand how FUS KO impacts 
UPF1’s RNA binding ability, we performed a UPF1 RNA IP. UPF1 protein was used as 
bait and was pulled down with bound RNA. We used rt-qPCR to measure the binding of 
the following mRNA species: UPF1, UPF3b, UPF2, SMG6, and SMG7 (Fig. 5.7A-E). FUS 
KO reduced UPF1 binding to all selected mRNA, including FUS mRNA itself. Moreover, 
re-expression of WT FUS rescued UPF1 binding to the selected mRNA. Western blot 
confirming UPF1 Immunoprecipitation can be found in Fig 5.9 since the same UPF1 RNA 
IP samples were used for both sets of experiments in Fig 5.7 and 5.9. 
 It is likely that FUS plays an important role in mediating UPF1/RNA interaction. 
Based on our selected mRNA, it is possible, that NMD autoregulation is shifted toward 
pathway upregulation by FUS KO. Upregulation of NMD would be logical due to splicing 
defects that occur when FUS is lost. However, FUS KO could also cause reduced 
transcription of NMD factors. Thus, the data are complex and cannot be explained simply 
by shifted NMD autoregulation alone.  
 NMD Substrate mRNAs are Stabilized when FUS is Knocked Out 
 Our observation of reduced complex NMD formation (Fig 5.4) led us to question 
if the NMD pathway is functional when FUS is knocked out. Thus, we examined the 
stability of selected NMD substrates ATF3, ATF4, and TBL2 in FUS WT, KO, and re-
expression cells. Using an actinomycin D time course assay paired with rt-qPCR, we found 
that ATF3, ATF4, and TBL2 (Fig. 5.8A-C) were stabilized when FUS is knocked out, 
suggesting reduced NMD activity. The stability of CyclophilinD, our control, remained 
consistent regardless of the presence of FUS (Fig. 5.8D). Additionally, re-expression of 
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FUS rescued the stabilization of these RNA species. These data suggest that FUS KO does 
result in reduced NMD activity. Downregulation of NMD factors and associated 
complexes would result in increased expression of ATF3, ATF4, and TBL2 through their 
stabilization.  
 FUS KO Reduces UPF1 Binding to NMD Substrate mRNA 
 Probing into UPF1’s binding ability to NMD substrates when FUS is knocked out 
may help us understand if FUS plays a role in target differentiation, thus we performed a 
UPF1 RNA IP to understand how FUS KO impacts UPF1’ RNA binding ability to NMD 
substrate mRNAs. After UPF1 protein was pulled down we used rt-qPCR to measure the 
binding of the following mRNA species: ATF3, ATF4, and TBL2. FUS KO reduced UPF1 
binding to all selected mRNAs (Fig. 5.9A-C), re-expression rescued UPF1 binding. It is 
noted that the UPF1 RNA IP in Fig 5.7 and 5.9 share the same western blot. The results 
suggest that the interaction between UPF1 and NMD substrates may require FUS for 
efficacious NMD, consistent with increased mRNA stabilities in Fig 5.8.  
 Natural NMD substrate levels are in influenced by FUS KO 
 With the reduced mRNA and protein levels of NMD factors (Fig. 5.3 and 5.5), 
reduced NMD complex formation (Fig. 5.4), reduced UPF1 binding to NMD substrates 
(Fig. 5.9), and increased mRNA stabilities of NMD substrates (Fig. 5.8), we would expect 
increased mRNA levels of these NMD substrates when FUS is knocked out. Thus, we 
measured the steady state levels of the NMD substrates previously published (214): ATF3, 
ATF4, and TBL2, as well as ATF6 and GADD45B (186). Surprisingly, the steady state 
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mRNA levels appear to be complex. For ATF3 (Fig. 5.10A), there was a modest, but 
insignificant increase in mRNA levels and reduction when FUS was re-expressed. While 
this followed the proposed trend, it was not statistically significant. ATF4 and TBL2 (Fig. 
5.10B, D) saw increased mRNA levels when FUS was knocked out, but upon re-expression 
mRNA levels increased further. ATF6 levels decreased following FUS KO and transcript 
levels partially recovered following rescue (Fig. 5.10C). GADD45B (Fig. 5.10E) 
demonstrated reduction of mRNA levels when FUS was knocked out and then further 
reductions when FUS was re-expressed. These results obviously are inconsistent with the 
above hypothesis solely based on NMD alone. The results suggest that FUS’ influence over 
the expression specific genes is more complicated than regulation of mRNA stability 
through NMD alone. It is likely that FUS’ ability to regulate gene expression is a gene-
specific mixture of its function in transcription, RNA splicing, RNA export, translation, 
and stability.  
5.3 Conclusions and Future Directions for FUS KO/ NMD Study 
 Overall, the results of this small study are promising, however, more work needs to 
be done to fully develop a mechanism by which endogenous FUS regulates NMD factor 
expression and its impact on downstream substrate stability. In our preliminary 
examination of FUS’ role, we aimed to demonstrate its function in modulating the 
expression NMD factor genes through the NMD pathways autoregulation. However, FUS’ 
cellular function is complex and encompasses nearly every aspect of canonical gene 
expression: transcription, splicing, translation, and mRNA stabilization. We were able to 
establish that FUS likely controls the expression of major NMD factors through 
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transcription, as KO of FUS does not impact the stability of their mRNA but reduces the 
steady levels of mRNA and proteins. We observed increased stability of endogenous NMD 
substrate, however, steady state levels of these mRNAs indicate that FUS may play a more 
intricate role in their expression as well.   
 Future studies to expand on these data should include both quantitative LC MS/MS 
and RNA-seq studies to examine changes in the protein and mRNA repertoire that occur 
when FUS is knocked out. Recently, studies exploring why motor neurons are uniquely 
susceptible to degeneration demonstrated vast differences in the proteome compared to 
oculomotor neurons, a subtype of motor neurons unaffected by disease. Downregulation 
of “supersaturated” proteins, including ion channels and proteins related to RNA 
metabolism contribute to neuronal dysfunction (216). Comparison of proteins and mRNA 
lost upon FUS KO to those known to be supersaturated may provide important clues as to 
which proteins are most heavily impacted. Functional and mechanistic experiments 
following up these large-omic studies may include deeper dives into molecular pathways 
negatively impacted by both loss of FUS and ALS.  
 Additionally, studies exploring the biochemical and molecular interaction between 
UPF1 and FUS will be critical for understanding UPF1’s newly described role in the 
nucleus and in ALS(217). A recently published study illustrates a novel aspect of UPF1 
function in the nucleus that seems to mirror FUS’. Like FUS, UPF1 has been demonstrated 
to cluster with nascent transcripts, and RNAP II and III (14, 106, 217). Similarly, UPF1 
demonstrated to be important for efficient polyadenylation and release of new transcripts, 
RNP assembly, and RNA export. Deeper exploration into the interactions between UPF1 
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and WT or mutant FUS (214) (Fig 5.9D) will likely yield important information as to how 
FUS directly plays a role in NMD and how mutants disturb the pathway.  
 We conclude that endogenous FUS plays an important role in mediating NMD 
activity through transcriptional regulation of NMD factors (Fig 5.3, 5.5, and 5.6). This is 
supported by the stabilization of endogenous NMD substrates ATF3, ATF4, and TBL2 
when FUS is knocked out (Fig 5.8). In addition, FUS appears to regulate mRNA levels at 
different levels in fine tuning the final mRNA and protein levels of these genes. 
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Figure 5.1 Endogenous FUS binds key NMD factor mRNA 
Wild type N2a cells and N2a FUS knockout (NCF) cells were lysed and FUS was 
immunoprecipitated. mRNA bound to endogenous FUS was measured using rt-qPCR (A-
D). The levels of the indicated mRNA were quantified by qPCR using the cycle threshold 
(ΔΔCT) method, and the fold changes compared with NCF are presented. *P ≤ 0.05; ***P 
≤ 0.001. A Student’s t test was used to determine P values. 
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Figure 5.2 Endogenous FUS binds NMD substrate mRNA 
Wild type N2a cells and N2a FUS knockout (NCF) cells were lysed and FUS was 
immunoprecipitated. mRNA bound to endogenous FUS was measured using rt-qPCR (A-
C). The levels of the indicated mRNA were quantified by qPCR using the cycle threshold 
(ΔΔCT) method, and the fold changes compared with NCF are presented. *P ≤ 0.05; **P 
≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values. 
  
D. 
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Figure 5.3 Endogenous FUS is required for normal expression of NMD factor protein 
NMD factors were blotted for in WT N2a, NCF, and FLAG FUS rescue cells to examine 
their steady state levels. Immunoblots of the following proteins are shown: SMG1, SMG5, 
SMG6, and SMG7 (A), UPF1, UPF2, UPF3b, and UPF3a (B), and XRN1, eIF4A3,  
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Figure 5.3 continued 
RNPS1, endogenous FUS, FLAG FUS, and Actin (C). Quantitative results are shown in 
D. Protein intensities were normalized to actin and compared with N2a. *P ≤ 0.05; **P ≤ 
0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values. 
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Figure 5.4 Endogenous FUS is required for assembly of NMD factor complexes 
NMD factors coprecipitated with endogenous UPF1 from WT N2a, NCF, and FLAG FUS 
rescue cells. Immunoblots of UPF1, p-UPF1, UPF3b, SMG6, SMG7, endogenous FUS, 
FLAG-FUS, and GAPDH are shown in A, and quantitative results are shown in B. Protein 
intensities were normalized to corresponding UPF1 bands and compared with N2a. *P ≤ 
0.05; **P ≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values. 
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Figure 5.5 Endogenous FUS is required for normal expression of NMD factor mRNA 
mRNA from WT N2a, NCF, and FLAG FUS rescue cells were collected and steady state 
levels measured using rt-qPCR (A-G). The levels of the indicated mRNA were quantified 
by qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with 
N2a are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to 
determine P values. 
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Figure 5.6 NMD factor mRNA stability is unchanged when FUS is Knocked Out 
Turnover rates of UPF1 (A), UPF3b (B), SMG6 (C), and SMG7 (D) mRNAs in WT N2a, 
NCF, or FLAG FUS rescue cells. Actinomycin D or DMSO control was added 1, 2, or 3 
hr before harvesting for RNA isolation. Individual mRNAs of interest were quantified by 
qPCR, normalized against RPL13a, and presented as fold change versus DMSO treatment 
over time. Error bars represent the SD from three replicates. ANOVA with a post hoc 
Tukey honest significant difference test was used.  
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Figure 5.7 FUS KO Reduces UPF1 Binding to NMD Factor mRNA 
WT N2a, NCF, or FLAG FUS rescue cells lysate was subjected to IP using normal goat 
serum (NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot 
and qPCR quantification comparing RNA coprecipitated with UPF1 protein versus NGS 
control. UPF1 IP from WT N2a, NCF, or FLAG FUS rescue cells was performed, followed 
by Western blot (Fig. 5.10) and qPCR measurement of UPF1 (A), UPF2 (B), UPF3b (C),  
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Figure 5.7 continued 
SMG6 (D), and SMG7 (E) mRNAs. The levels of the indicated mRNA were quantified by 
qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with N2a 
are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA with 
a post hoc Tukey honest significant difference test was used to determine P values. 
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Figure 5.8 NMD substrate mRNA is stabilized when FUS is Knocked Out 
Turnover rates of ATF3 (A), ATF4 (B), TBL2 (C), and CyclophilinD (D) mRNAs in WT 
N2a, NCF, or FLAG FUS rescue cells. Actinomycin D or DMSO control was added 1, 2, 
or 3 hr before harvesting for RNA isolation. Individual mRNAs of interest were quantified 
by qPCR, normalized against RPL13a, and presented as fold change versus DMSO 
treatment over time. Error bars represent the SD from three replicates. *, # P ≤ 0.05; **, 
##P ≤ 0.005; ***, ###P ≤ 0.001. A Student’s t test was used to determine P values. * 
represent significance compared to N2a, # represent significance compared to NCF. 
  
 
 
132
 
Figure 5.9 UPF1 Binding to NMD Substrate mRNA is Reduced When FUS is Knocked 
Out 
WT N2a, NCF, or FLAG FUS rescue cells lysate was subjected to IP using normal goat 
serum (NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot 
and qPCR quantification comparing RNA coprecipitated with UPF1 protein versus NGS 
control. UPF1 IP from WT N2a, NCF, or FLAG FUS rescue cells was performed, followed 
by Western blot (Fig. 5.10) and qPCR measurement of ATF3 (A), ATF4 (B), and TBL2 
mRNAs. UPF1, FUS, and GAPDH were assessed by Western blot, as shown in D. The 
levels of the indicated mRNA were quantified by qPCR using the cycle threshold (ΔΔCT) 
method, and the fold changes compared with N2a are presented. *P ≤ 0.05; **P ≤ 0.005;  
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Figure 5.9 continued 
***P ≤ 0.001. N.S., not significant. ANOVA with a post hoc Tukey honest significant 
difference test was used to determine P values. 
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Figure 5.10 Natural NMD substrate levels are in influenced by FUS KO 
mRNA from WT N2a, NCF, and FLAG FUS rescue cells were collected and steady state 
levels measured using rt-qPCR (A-E). The levels of the indicated mRNA were quantified 
by qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with  
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Figure 5.10 continued 
N2a are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA 
with a post hoc Tukey honest significant difference test was used to determine P values.  
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